[go: up one dir, main page]

WO2006064199A1 - Procede ameliore de detection de nucleotides - Google Patents

Procede ameliore de detection de nucleotides Download PDF

Info

Publication number
WO2006064199A1
WO2006064199A1 PCT/GB2005/004776 GB2005004776W WO2006064199A1 WO 2006064199 A1 WO2006064199 A1 WO 2006064199A1 GB 2005004776 W GB2005004776 W GB 2005004776W WO 2006064199 A1 WO2006064199 A1 WO 2006064199A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
buffer
incorporated
nucleotides
nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2005/004776
Other languages
English (en)
Inventor
Milan Fedurco
Anthony Romieu
Gerardo Turcatti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Solexa Ltd Great Britain
Original Assignee
Solexa Ltd Great Britain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36123236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006064199(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0427236.5A external-priority patent/GB0427236D0/en
Application filed by Solexa Ltd Great Britain filed Critical Solexa Ltd Great Britain
Priority to EP05818529.9A priority Critical patent/EP1828412B2/fr
Priority to US11/792,878 priority patent/US9217178B2/en
Publication of WO2006064199A1 publication Critical patent/WO2006064199A1/fr
Anticipated expiration legal-status Critical
Priority to US14/295,039 priority patent/US9303290B2/en
Priority to US15/050,337 priority patent/US9970055B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing

Definitions

  • the invention relates to an additive which can be added to buffers used in nucleotide detection processes and improved methods of nucleic acid sequencing using this additive.
  • the invention relates to use of the additive to improve the efficiency of fluorescence-based multiple cycle nucleic acid sequencing reactions.
  • nucleic acid sequencing based on successive cycles of incorporation of fluorescently labelled nucleic acid analogues.
  • identity of the added base is determined after each nucleotide addition by detecting the fluorescent label .
  • US 5,302,509 describes a method for sequencing a polynucleotide template which involves performing multiple extension reactions using a DNA polymerase or DNA ligase to successively incorporate labelled polynucleotides complementary to a template strand.
  • a new polynucleotide strand based-paired to the template strand is built up in the 5 ' to 3 ' direction by successive incorporation of individual nucleotides complementary to the template strand.
  • the substrate nucleoside triphosphates used in the sequencing reaction are labelled at the 3' position with different 3 1 labels, permitting determination of the identity of the incorporated nucleotide as successive nucleotides are added.
  • the present inventors have developed methods of sequencing multiple nucleic acid molecules in parallel based on the use of arrays, wherein multiple template molecules immobilised on the array are sequenced in parallel.
  • arrays may be single molecule arrays or clustered arrays.
  • the inventors have observed that when performing sequencing-by-synthesis using fluorescently labelled nucleotide analogues the brightness of the incorporated fluorophore diminishes at each cycle of nucleotide addition. This is a particular problem when sequencing nucleic acid templates on arrays, and more particularly arrays comprised of clusters of surface-bound DNA. Cycles of sequencing may stop at around cycle 8-10 due to loss of signal from the fluorescently labelled nucleotide analogue incorporated into extended strand complementary to the template, making it difficult to score accurately the identity of the incorporated base. Moving to a new area of the array that has not been previously scanned however clearly shows that the correct base can be accurately read.
  • antioxidants such as ascorbic acid (vitamin C)
  • fluorescent imaging buffers It has, however, never previously been suggested to add such antioxidants to buffers used for detection/imaging of fluorophores incorporated in or attached to nucleic acid. More particularly, it has never previously been suggested to use antioxidants such as ascorbate as additives in buffers used for imaging of arrays during cycles of nucleic acid sequencing.
  • the inventors have now observed that the presence of one or more antioxidants in buffers used in any molecular biology technique requiring detection of a fluorescent moiety incorporated in or attached to a nucleic acid, which detection includes repeated or prolonged exposure to intense illumination, is surprisingly advantageous.
  • the invention provides a method of detecting a fluorescent moiety incorporated in or attached to a polynucleotide molecule, wherein the method includes a detection step which requires repeated or prolonged exposure to intense illumination, and wherein detection of the fluorescent moiety is carried out in a buffer which comprises one or more antioxidants.
  • the method of the invention is useful in many techniques requiring incorporation of a fluorescently labeled nucleotide into a polynucleotide, including but not limited to sequencing reactions, polynucleotide synthesis, nucleic acid amplification, nucleic acid hybridisation assays, single nucleotide polymorphism studies, and other - A -
  • the method is a sequencing reaction, particularly a sequencing-by-synthesis reaction.
  • the method of invention is of particular utility in- a -method--of sequencing a template nucleic acid comprising incorporating one or more fluorescently labelled nucleotides into a strand of nucleic acid complementary to said template nucleic acid and determining the identity of the base present in one or more of the incorporated nucleotide (s) , wherein the step of determining the identity of the base present in the incorporated nucleotide (s) is carried out in a buffer which comprises one or more antioxidants.
  • At least one of the one or more antioxidants is ascorbic acid or a salt, analogue, or derivative thereof.
  • ascorbate and “ascorbic acid” as used herein refer to both the L-isomer and the D-isomer, and mixtures, including racemic mixtures, thereof. Both optical isomers are capable of functioning as antioxidants.
  • a preferred salt includes sodium ascorbate, e.g. sodium L-ascorbate.
  • ⁇ -Suitable derivatives and analogues include those in which the 5- and/or 6-hydroxy group is esterified or otherwise derivatised.
  • the 5- and/or 6-hydroxy group may be replaced with an alternative functional group, such as halo or amino.
  • Other alternative derivatives are those in which the 5- and/or 6-hydroxy group is absent and (i.e with a hydrogen atom in place of the hydroxyl group) .
  • Representative examples of such derivatives include, but are not limited to, 6-O-tosyl-L-ascorbate, 5-deoxy-L-ascorbate, 6-bromo-6- deoxy-L-ascorbate, 6-amino-6-deoxy-L-ascorbate, L-ascorbic acid 6-carboxylate, and 6-0-ascorbyl alkanoates such as 6- ascorbyl palmitate (palmitoyl ascorbate) .
  • a combination of two or more antioxidants may be present in the buffer.
  • at least one of the antioxidants in such combinations is ascorbic acid or a salt, analogue, or derivative thereof as discussed immediately hereinbefore
  • the one or more antioxidants will be present in the buffer at a concentration of at least 10 mM, preferably at least 20 mM. Whilst there is no particular upper limit, generally a concentration of 100 mM, more particularly a concentration of 50 mM, represents a preferable upper limit to the concentration of antioxidant present. For example, therefore, the one or more antioxidants may be present in the buffer at a concentration in the range of from 10 to 100 mM, preferably 20 to 50 mM, more preferably about 50 mM.
  • the pH of the buffer is not of critical importance; the invention may be operated at a fairly broad pH range. Generally, however, broadly neutral pH ranges are appropriate for the buffers, such as from about pH 5 to about pH 9, preferably from pH 5.5 to 8.6, e.g. about pH -7.
  • the nature of the buffering agent itself is likewise not of any great importance: any buffering agent may be used.
  • An example of an appropriate, indeed a preferred convenient buffering agent is tris (tris (hydroxymethyl) aminomethane) .
  • salts e.g. sodium chloride or any other convenient salt, for example present at a concentration in the range of from 5-100 mM, preferably 10-70 mM, and particularly 30 mM, may be present.
  • An example of a particularly preferred buffer which may be used in all aspects of the invention comprises Tris (10OmM) , NaCl (3OmM), sodium ascorbate (5OmM) at pH 7.
  • the nucleotide (s) incorporated into the strand of nucleic acid complementary to the template nucleic are each fluorescently labelled. The inclusion of a fluorescent label facilitates detection/identification of the base present in the incorporated nucleotide (s) . Appropriate fluorophores are well known in the art.
  • the labels may be the same for each type of nucleotide, or each nucleotide type may carry a different label. This facilitates the identification of incorporation of a particular nucleotide. Thus, for example modified adenine, guanine, cytosine and thymine would all have attached a different fluorophore to allow them to be discriminated from one another readily. When sequencing on arrays, a mixture of labelled and unlabelled nucleotides may be used.
  • Detectable labels such as fluorophores can be linked to nucleotides via the base using a suitable linker.
  • the linker may be acid labile, photolabile or contain a disulfide linkage.
  • Preferred labels and linkages include those disclosed in WO03/048387.
  • Other linkages, in particular phosphlne-cleavable azide-containing linkers, may be employed in the invention as described in greater detail in WO2004/018493. The contents of WO 03/048387 and WO
  • the nucleotides described in WO2004/018493 comprise a purine or pyrimidine base and a ribose or deoxyribose sugar moiety which has a removable blocking group covalently attached thereto, preferably at the 3'0 position.
  • 3' blocking groups are also described in WO2004/018497, the contents of which is also incorporated herein in its entirety by reference. Use of such 3 ' -blocked nucleotides permits controlled incorporation of nucleotides in a stepwise manner, since the presence of a blocking group at the 3 ' -OH position prevents incorporation of additional nucleotides.
  • the detectable label may, if desirable, be incorporated into the blocking groups as is disclosed in WO2004/018497.
  • Methods for detecting fluorescently labelled nucleotides generally require use of incident light (e.g. laser light) of a wavelength specific for the fluorescent label, or the use of other suitable sources of illumination, to excite the fluorophore. Fluorescent light emitted from the fluorophore may then be detected at the appropriate wavelength using a suitable detection system such as for example a Charge-Coupled-Device (CCD) camera, which can optionally be coupled to a magnifying device, a fluorescent imager or a ' confocal microscope.
  • incident light e.g. laser light
  • CCD Charge-Coupled-Device
  • detection of an incorporated base may be carried out by using a confocal scanning microscope to scan the surface of the array with a laser, to image fluorescent labels attached to the incorporated nucleotide (s) .
  • a sensitive 2-D detector such as a charge-coupled detector (CCD)
  • CCD charge-coupled detector
  • This technique is particularly useful with single molecule arrays .
  • Other techniques such as scanning near-field optical microscopy (SNOM) are available and may be used when imaging dense arrays. For a description of scanning near-field optical microscopy, see Moyer et al. , Laser Focus World 29:10, 1993.
  • TRFM total internal reflection fluorescence microscopy
  • Detection buffers containing antioxidants show a clear improvement (over corresponding buffers absent such antioxidants) at preventing light-induced chemical artefacts in cycles of sequencing-by-synthesis based on detection of fluorescentIy labelled nucleotide analogues.
  • antioxidants prevents/reduces light-induced chemical reactions from damaging the integrity of the nucleic acid template and allows accurate determination of the identity of the incorporated base over at least 2, preferably at least 10, and more preferably at least 16 cycles of nucleotide incorporation.
  • Preferably from 10 to 30 and more preferably from 16 to 30 nucleotides are successively incorporated, and identified, in the sequencing reaction.
  • the ability to accurately sequence 10 or more, and preferably 16 or more, consecutive nucleotides in a sequencing reaction is a significant advantage in applications such as genome re-alignment.
  • sequencing reaction In the context of this invention the terms “sequencing reaction”, “sequencing methodology” or “method of sequencing” generally refer to any polynucleotide
  • “sequencing-by-synthesis” reaction which involves sequential addition of one or more nucleotides to a growing polynucleotide chain in the 5' to 3 ' direction using a polymerase in order to form an extended polynucleotide chain complementary to the template nucleic acid to be sequenced.
  • the identity of the base present in one or more of the added nucleotide (s) is determined in a detection or "imaging” step.
  • the identity of the added base is preferably determined after each nucleotide incorporation step.
  • the sequence of the template may then be inferred using conventional Watson-Crick base-pairing rules.
  • “sequencing” can also encompass incorporation and identification of a single nucleotide. Determination of the identity of a single base may be useful, for example, in the scoring of single nucleotide polymorphisms.
  • the nucleic acid template to be sequenced in a sequencing reaction may be any polynucleotide that it is desired to sequence.
  • the nucleic acid template for a sequencing reaction will typically comprise a double- stranded region having a free 3 ' hydroxyl group which serves as a primer or initiation point for the addition of further nucleotides in the sequencing reaction.
  • the region of the template to be sequenced will overhang this free 3 ' hydroxyl group on the ' complementary strand.
  • the primer bearing the free 3 ' hydroxyl group may be added as a separate component (e.g. a conventional oligonucleotide sequencing primer) which hybridises to a region of the template to be sequenced.
  • the primer and the template strand to be sequenced may each form part of a partially self-complementary nucleic acid strand capable of forming an intramolecular duplex, such as for example a hairpin loop structure.
  • Nucleotides are added successively to the free 3 ' hydroxyl group, resulting in synthesis of a polynucleotide chain in the 5 1 to 3 ' direction. After each nucleotide addition the nature of the base which has been added may be determined, thus providing sequence information for the nucleic acid template.
  • incorporation of a nucleotide into a nucleic acid strand (or polynucleotide) refers to joining of the nucleotide to the free 3 ' hydroxyl group of the nucleic acid strand via formation of a phosphodiester linkage with the 5 ' phosphate group of the nucleotide.
  • the nucleic acid template to be sequenced may be DNA or RNA, or even a hybrid molecule comprised of deoxynucleotides and ribonucleotides.
  • the nucleic acid may comprise naturally occurring and/or non-naturally occurring nucleotides and natural or non-natural backbone linkages.
  • Nucleic acid templates to be sequenced may be attached to a solid support via any suitable linkage method known in the art. Preferably linkage will be via covalent attachment. If the templates are "arrayed" on a solid support then the array may take any convenient form. Thus, the method of the invention is applicable to all types of "high density" arrays, including single-molecule arrays and clustered arrays.
  • immobilisation When referring to immobilisation of molecules (e.g. nucleic acids) to a solid support, the terms “immobilised” and “attached” are used interchangeably herein and both terms are intended to encompass direct or indirect, covalent or non-covalent attachment, unless indicated otherwise, either explicitly or by context.
  • covalent attachment may be preferred, but generally all that is required is that the molecules (e.g. nucleic acids) remain immobilised or attached to the support under the conditions in which it is intended to use the support, for example in applications requiring nucleic acid amplification and/or sequencing.
  • Certain embodiments of the invention may make use of solid supports comprised of an inert substrate or matrix (e.g.
  • biomolecules such as polynucleotides
  • supports include, but are not limited to, polyacrylamide hydrogels supported on an inert substrate such as glass, particularly polyacrylamide hydrogels as described in WO 2005/065814, the contents of which are incorporated herein in their entirety by reference.
  • the biomolecules e.g. polynucleotides
  • the intermediate material e.g. the hydrogel
  • the intermediate material may itself be non-covalently attached to the substrate or matrix (e.g. the glass substrate) .
  • covalent attachment to a solid support is to be interpreted accordingly as encompassing this type of arrangement.
  • the method of the invention may be used for sequencing on essentially any type of array formed by immobilisation of nucleic acid molecules on a solid support, and more particularly any type of high-density array.
  • the method of the invention is particularly advantageous in the context of sequencing on clustered arrays.
  • distinct regions on the array comprise multiple polynucleotide template molecules.
  • each site on the array may comprise multiple copies of one individual polynucleotide molecule or even multiple copies of a small number of different polynucleotide molecules (e.g. multiple copies of two complementary nucleic acid strands) .
  • Multi-polynucleotide or clustered arrays of nucleic acid molecules may be produced using techniques generally known in the art.
  • WO 98/44151 and WO 00/18957 both describe methods of solid-phase nucleic acid amplification which allow amplification products to be immobilised on a solid support in order to form arrays comprised of clusters or "colonies" of immobilised nucleic acid molecules.
  • Each cluster or colony on such an array is formed from a plurality of identical immobilised polynucleotide strands and a plurality of identical immobilised complementary polynucleotide strands.
  • the arrays so-formed are generally referred to herein as "clustered arrays" .
  • the nucleic acid molecules present on the clustered arrays prepared according to these methods are suitable templates for sequencing using the method of the invention. However, the invention is not intended to use of the method in sequencing reactions carried out on clustered arrays prepared according to these specific methods.
  • bridged structures formed by annealing of pairs of immobilised polynucleotide strands and immobilised complementary strands, both strands being immobilised on the solid support at the 5 ! end, preferably via a covalent attachment.
  • linearisation The process of removing all or a portion of one immobilised strand in a "bridged" double-stranded nucleic acid structure may be referred to herein as "linearisation” .
  • bridged template structures may be linearised by cleavage of one or both strands with a restriction endonuclease and this method of linearisation may be used in the context of the invention.
  • restriction enzymes for linearisation is that it requires the presence of a specific recognition sequence for the enzyme at a suitable location in the bridged template structure. There is a risk that the same recognition sequence may appear elsewhere in the bridged structure, meaning that the enzyme may cut at one or more further sites, in addition to the intended cleavage site for linearisation.
  • bridged structures to be linearised are derived by solid- phase amplification of templates of unknown or partially- unknown sequence, since it cannot be predicted in advance whether a particular enzyme will cut within the region of unknown sequence.
  • the inventors have developed a number of alternative cleavage methods for template linearisation which do not require the use of restriction enzymes, as described below. Any of these methods can be used for linearisation of "bridged" nucleic acid structures in clustered arrays formed by solid-phase amplification, and indeed for linearisation any "bridged" double-stranded nucleic acid molecule formed by annealing of complementary polynucleotide strands that are attached to a solid support at the 5 ' end, whether or not formed by solid-phase amplification.
  • another aspect the invention provides a method of generating a template for a nucleic acid sequencing reaction comprising, (i) providing at least one double-stranded nucleic acid molecule, wherein both strands of the double-stranded nucleic acid molecule are attached to the solid support at the 5' end,
  • step (ii) cleaving one or both strands of the double-stranded nucleic acid molecule, and (iii) subjecting the cleaved strand(s) to denaturing conditions to remove the portion of the cleaved strand(s) not attached to the solid support, thereby generating a partially or substantially single-stranded template for a nucleic acid sequencing reaction, characterised in that step (ii) does not comprise cleavage with a restriction endonuclease or a nicking endonuclease.
  • the double-stranded nucleic acid molecule is typically a bridged nucleic acid structure produced by a solid-phase nucleic acid amplification method.
  • cleavage may occur at a cleavage site in one or both strands of the double-stranded nucleic acid molecule which comprises one or more or any combination of non-natural nucleotides, ribonucleotides or a non-nucleotide chemical modifications.
  • Preferred cleavage methods are as follows:
  • chemical cleavage encompasses any method which utilises a non-nucleic acid and non-enzymatic chemical reagent in order to promote/achieve cleavage of one or both strands of a double-stranded nucleic acid molecule.
  • one or both strands of the double-stranded nucleic acid molecule may include one or more non-nucleotide chemical moieties and/or non-natural nucleotides and/or non- natural backbone linkages in order to permit chemical cleavage reaction.
  • the modification(s) required to permit chemical cleavage may be incorporated into an amplification primer used in solid- phase nucleic acid amplification.
  • one strand of the double-stranded nucleic acid molecule may include a diol linkage which permits cleavage by treatment with periodate
  • Diol linker units based on phosphoamidite chemistry suitable for incorporation into polynucleotide chains are commercially available from Fidelity systems Inc. (Gaithersburg, MD, USA) .
  • One or more diol units may be incorporated into a polynucleotide using standard methods for automated chemical DNA synthesis.
  • oligonucleotide primers including one or more diol linkers can be conveniently prepared by chemical synthesis.
  • one or more spacer molecules may be included between the diol linker and the site of attachment to the solid support.
  • the spacer molecule may be a non-nucleotide chemical moiety. Suitable spacer units based on phosphoamidite chemistry for use in conjunction with diol linkers are also supplied by Fidelity Systems Inc.
  • One suitable spacer for use with diol linkers is the spacer denoted arm 26, identified in the accompanying examples.
  • To enable attachment to a solid support at the 5 ' end of the polynucleotide strand arm 26 may be modified to include a phosphorothioate group.
  • the phosphorothioate group can easily be attached during chemical synthesis of a "polynucleotide" chain including the spacer and diol units.
  • Other spacer molecules could be used as an alternative to arm 26.
  • a stretch of non-target "spacer" nucleotides may be included. Typically from 1 to 20, more preferably from 1 to 15 or from 1 to 10, and more particularly 2, 3, 4, 5, 6, 7, 8, 9 or 10 spacer nucleotides may be included. Most preferably 10 spacer nucleotides will be positioned between the point of attachment to the solid support and the diol linker. It is preferred to use polyT spacers, although other nucleotides and combinations thereof can be used.
  • the primer may include 1OT spacer nucleotides.
  • the diol linker is cleaved by treatment with a "cleaving agent", which can be any substance which promotes cleavage of the diol.
  • the preferred cleaving agent is periodate, preferably aqueous sodium periodate (NaIO 4 ) .
  • the cleaved product may be treated with a "capping agent” in order to neutralise reactive species generated in the cleavage reaction.
  • Suitable capping agents for this purpose include amines, such as ethanolamine.
  • the capping agent e.g. ethanolamine
  • the capping agent may be included in a mixture with the cleaving agent (e.g. periodate) so that reactive species are capped as soon as they are formed.
  • a diol linkage and cleaving agent e.g. periodate
  • cleaving agent e.g. periodate
  • utility of diol linkages/periodate as a method of linearisation is not limited to polyacrylamide hydrogel surfaces but also extends to linearisation of nucleic acids immobilised on other solid supports and surfaces, including supports coated with functionalised silanes (etc) .
  • the strand to be cleaved may include a disulphide group which permits cleavage with a chemical reducing agent, e.g. Tris (2-carboxyethyl) -phosphate hydrochloride (TCEP) .
  • TCEP Tris (2-carboxyethyl) -phosphate hydrochloride
  • abasic site is defined as a nucleoside position in a polynucleotide chain from which the base component has been removed.
  • Abasic sites can occur naturally in DNA under physiological conditions by hydrolysis of nucleoside residues, but may also be formed chemically under artificial conditions or by the action of enzymes. Once formed, abasic sites may be cleaved (e.g. by treatment with an endonuclease or other single-stranded cleaving enzyme, exposure to heat or alkali) , providing a means for site-specific cleavage of a polynucleotide strand.
  • an abasic site may be created at a pre-determined position on one strand of a double-stranded polynucleotide and then cleaved by first incorporating deoxyuridine (U) at a pre-determined cleavage site in one strand of the double-stranded nucleic acid molecule.
  • U deoxyuridine
  • This can be achieved, for example, by including U in one of the primers used for preparation of the double-stranded nucleic acid molecule by solid-phase PCR amplification.
  • the enzyme uracil DNA glycosylase (IJDG) may then be used to remove the uracil base, generating an abasic site on one strand.
  • the polynucleotide strand including the abasic site may then be cleaved at the abasic site by treatment with endonuclease (e.g EndoIV endonuclease, AP lyase, FPG glycosylase/AP lyase, EndoVIII glycosylase/AP lyase), heat or alkali.
  • endonuclease e.g EndoIV endonuclease, AP lyase, FPG glycosylase/AP lyase, EndoVIII glycosylase/AP lyase
  • Abasic sites may also be generated at non- natural/modified deoxyribonucleotides other than deoxyuridine and cleaved in an analogous manner by treatment with endonuclease, heat or alkali.
  • endonuclease heat or alkali.
  • 8-oxo- guanine can be converted to an abasic site by exposure to FPG glycosylase.
  • Deoxyinosine can be converted to an abasic site by exposure to AIkA glycosylase.
  • the abasic sites thus generated may then be cleaved, typically by treatment with a suitable endonuclease (e.g. EndoIV, AP lyase) .
  • endonuclease e.g. EndoIV, AP lyase
  • the non-natural/modified nucleotide should be capable of being copied by the polymerase used for the amplification reaction.
  • the molecules to be cleaved may be exposed to a mixture containing the appropriate glycosylase and one or more suitable endonucleases.
  • the glycosylase and the endonuclease will typically be present in an activity ratio of at least about 2: 1.
  • This method of cleavage has particular advantages in relation to the creation of templates for nucleic acid sequencing.
  • cleavage at an abasic site generated by treatment with a glycosylase such as UDG generates a free 3 ' hydroxyl group on the cleaved strand which can provide an initiation point for sequencing a region of the complementary strand.
  • a glycosylase such as UDG
  • UDG glycosylase
  • deoxyuridine which does not occur naturally in DNA, but is otherwise independent of sequence context, if only one non-natural base is included there is no possibility of glycosylase-mediated cleavage occurring elsewhere at unwanted positions in the duplex.
  • the enzyme may create nicks at "other" sites in the duplex (in addition to the desired cleavage site) if these possess the correct recognition sequence.
  • a non-natural nucleotide e.g. U
  • Oligonucleotide primers including U nucleotides, and the other non-natural nucleotides listed above, can easily be prepared using conventional techniques and apparatus for chemical synthesis of oligonucleotides.
  • incorporation of one or more ribonucleotides into a polynucleotide strand which is otherwise comprised of deoxyribonucleotides can provide a site for cleavage using a chemical agent capable of selectively cleaving the phosphodiester bond between a deoxyribonucleotide and a ribonucleotide or using a ribonuclease (RNAse) .
  • RNAse ribonuclease
  • sequencing templates can be produced by cleavage of one strand of a "bridged" structure at a site containing one or more consecutive ribonucleotides using such a chemical cleavage agent or an RNas ⁇ .
  • the strand to be cleaved contains a single ribonucleotide to provide a site for chemical cleavage.
  • Suitable chemical cleavage agents capable of selectively cleaving the phosphodiester bond between a deoxyribonucleotide and a ribonucleotide include metal ions, for example rare-earth metal ions (especially La 3+ , particularly Tm 3+ , Yb 3+ or Lu 3+ (Chen et al . Biotechniques. 2002, 32: 518-520; Komiyama et al. Chem. Commun. 1999, 1443- 1451)), Fe(3) or Cu(3) , or exposure to elevated pH, e.g. treatment with a base such as sodium hydroxide.
  • a base such as sodium hydroxide
  • cleavage of the phosphodiester bond between a deoxyribonucleotide and a ribonucleotide is meant that the chemical cleavage agent is not capable of cleaving the phosphodiester bond between two deoxyribonucleotides under the same conditions.
  • the base composition of the ribonucleotide (s) is generally not material, but can be selected in order to optimise chemical (or enzymatic) cleavage.
  • rUMP or rCMP are generally preferred if cleavage is to be carried out by exposure to metal ions, especially rare earth metal ions.
  • the ribonucleotide (s) will typically be incorporated into one strand of a "bridged" double-stranded nucleic acid molecule (or the amplification primer from which this strand is derived if prepared by solid-phase amplification) , and may be situated in a region of the bridged structure which is single-stranded when the two complementary strands of the double-stranded molecule are annealed (i.e. in a 5' overhanging portion) .
  • the double-stranded nucleic acid molecule is prepared by solid-phase PCR amplification using forward and reverse amplification primers, one of which contains at least one ribonucleotide
  • the standard DNA polymerase enzymes used for PCR amplification are not capable of copying ribonucleotide templates.
  • the PCR products will contain an overhanging 5' region comprising the ribonucleotide (s) and any remainder of the amplification primer upstream of the ribonucleotide(s) .
  • the phosphodiester bond between a ribonucleotide and a deoxyribonucleotide or between two ribonucleotides may also be cleaved by an RNase .
  • Any endocytic ribonuclease of appropriate substrate specificity can be used for this purpose. If the ribonucleotide (s) are present in a region which is single-stranded when the two complementary strands of the double-stranded molecule are annealed (i.e. in a 5' overhanging portion) , then the RNase will be an endonuclease which has specificity for single strands containing ribonucleotides.
  • ribonuclease For cleavage with ribonuclease it is preferred to include two or more consecutive ribonucleotides, and preferably from 2 to 10 or from 5 to 10 consecutive ribonucleotides.
  • the precise sequence of the ribonucleotides is generally not material, except that certain RNases have specificity for cleavage after certain residues. Suitable RNases include, for example, RNaseA, which cleaves after C and U residues. Hence, when cleaving with RNaseA the cleavage site must include at least one ribonucleotide which is C or U.
  • Polynucleotides incorporating one or more ribonucleotides can be readily synthesised using standard techniques for oligonucleotide chemical synthesis with appropriate ribonucleotide precursors. If the double- stranded nucleic acid molecule is prepared by solid-phase nucleic acid amplification, then it is convenient to incorporate one or more ribonucleotides into one of the primers to be used for the amplification reaction.
  • photochemical cleavage encompasses any method which utilises light energy in order to achieve ⁇ cleavage of one or both strands of the double-stranded nucleic acid molecule.
  • a site for photochemical cleavage can be provided by a non-nucleotide chemical spacer unit in one of the strands of the double-stranded molecule (or the amplification primer from which this strand is derived if prepared by solid-phase amplification) .
  • Suitable photochemical cleavable spacers include the PC spacer phosphoamidite (4- (4,4'- Dimethoxytrityloxy)butyramidomethyl) -1- (2-nitrophenyl) - ethyl] -2-cyanoethyl- (N,N-diisopropyl) -phosphoramidite) supplied by Glen Research, Sterling, Virginia, USA (cat number 10-4913-XX) which has the structure:
  • the spacer unit can be cleaved by exposure to a UV light source.
  • This spacer unit can be attached to the 5' end of a polynucleotide, together with a thiophosphate group which permits attachment to a solid surface, using standard techniques for chemical synthesis of oligonucleotides.
  • this spacer unit can be incorporated into a forward or reverse amplification primer to be used for synthesis of a photocleavable double-stranded nucleic acid molecule by solid-phase amplification.
  • Site-specific cleavage of one strand of a double- stranded nucleic acid molecule may also be achieved by incorporating one or more methylated nucleotides into this strand and then cleaving with an endonuclease enzyme specific for a recognition sequence including the methylated nucleotide (s) .
  • the methylated nucleotide (s) will typically be incorporated in a region of one strand of the double- stranded nucleic acid molecule having a complementary stretch of non-methylated deoxyribonucleotides on the complementary strand, such that annealing of the two strands produces a hemimethylated duplex structure.
  • the hemimethylated duplex may then be cleaved by the action of a suitable endonuclease.
  • enzymes which cleave such hemimethylated target sequences are not to be considered as "restriction endonucleases" excluded from the scope of the second aspect of the invention, but rather are intended to form part of the subject-matter of the invention.
  • Polynucleotides incorporating one or methylated nucleotides may be prepared using standard techniques for automated DNA synthesis, using appropriately methylated nucleotide precursors. If the double-stranded nucleic acid molecule is prepared by solid-phase nucleic acid amplification, then it is convenient to incorporate one or more methylated nucleotides into one of the primers to be used for the amplification reaction. vi) PCR stoppers
  • the double- stranded nucleic acid may be prepared by solid-phase amplification using forward and reverse primers, one of which contains a "PCR stopper” .
  • a "PCR stopper” is any moiety (nucleotide or non-nucleotide) which prevents read- through of the polymerase used for amplification, such that it cannot copy beyond that point. The result is that amplified strands derived by extension of the primer containing the PCR stopper will contain a 5' overhanging portion. This 5' overhang (other than the PCR stopper itself) may be comprised of naturally occurring deoxyribonucleotides, with predominantly natural backbone linkages, i.e.
  • RNA cleavage reagent e.g. an enzyme
  • the PCR stopper may be essentially any moiety which prevents read-through of the polymerase to be used for the amplification reaction.
  • Suitable PCR stoppers include, but are not limited to, hexaethylene glycol (HEG) , abasic sites, and any non-natural or modified nucleotide which prevents read-through of the polymerase, including DNA analogues such as peptide nucleic acid (PNA) .
  • HOG hexaethylene glycol
  • PNA peptide nucleic acid
  • Stable abasic sites can be introduced during chemical oligonucleotide synthesis using appropriate spacer units containing the stable abasic site.
  • abasic furan (5 ' -O-Dimethoxytrityl-1 ⁇ ,2 ' -Dideoxyribose-3 ' - [ (2-cyanoethyl) - (N,N-diisopropyl) ] -phosphoramidite) spacers commercially available from Glen Research, Sterling, Virginia, USA, can be incorporated during chemical oligonucleotide synthesis in order to introduce an abasic site.
  • Such a site can thus readily be introduced into an oligonucleotide primer to be used in solid-phase amplification. If an abasic site is incorporated into either forward or reverse amplification primer the resulting amplification product will have a 5' overhang on one strand which will include the abasic site (in single-stranded form) .
  • the single-stranded abasic site may then be cleaved by the action of a suitable chemical agent (e.g. exposure to alkali) or an enzyme (e.g. AP-endonuclease VI, Shida el al. Nucleic Acids Research, 1996, Vol.24, 4572-4576) .
  • a cleavage site can also be introduced into one strand of the double-stranded nucleic molecule by preparing a conjugate structure in which a peptide molecule is linked to one strand of the nucleic acid molecule (or the amplification primer from which this strand is derived if prepared by solid-phase amplification) .
  • the peptide molecule can subsequently be cleaved by a peptidase enzyme of the appropriate specificity, or any other suitable means of non-enzymatic chemical or photochemical cleavage.
  • the conjugate between peptide and nucleic acid will be formed by covalently linking a peptide to one strand only of the double-stranded nucleic acid molecule, with the peptide portion being conjugated to the 5' end of this strand, adjacent to the point of attachment to the solid surface.
  • the peptide conjugate may be incorporated at the 5 ' end of one of the amplification primers. Obviously the peptide component of this primer will not be copied during PCR amplification, hence the "bridged" amplification product will include a cleavable 5' peptide "overhang" on one strand.
  • Conjugates between peptides and nucleic acids wherein the peptide is conjugated to the 5 1 end of the nucleic acid can be prepared using techniques generally known in the art.
  • the peptide and nucleic acid components of the desired amino acid and nucleotide sequence can be synthesised separately, e.g. by standard automated chemical synthesis techniques, and then conjugated in aqueous/organic solution.
  • the OPeCTM system commercially available from Glen Research is based on the "native ligation" of an N-terminal thioester- functionalized peptide to a 5'-cysteinyl oligonucleotide.
  • Pentafluorophenyl S-benzylthiosuccinate is used in the final coupling step in standard Fmoc-based solid-phase peptide assembly. Deprotection with trifluoroacetic acid generates, in solution, peptides substituted with an N-terminal S- benzylthiosuccinyl group.
  • 0-trans-4- (N-a-Fmoc-S-tert- butylsulfenyl-1-cysteinyl) aminocyclohexyl O-2-cyanoethyl- N,N-diisopropylphosphoramidite is used in the final coupling step in standard phosphoramidite solid-phase oligonucleotide assembly.
  • the conjugate strand containing peptide and nucleic acid can be covalently attached to a solid support using any suitable covalent linkage technique known in the art which is compatible with the chosen surface. If the peptide/nucleic acid conjugate structure is an amplification primer to be used for solid-phase PCR amplification, attachment to the solid support must leave the ' 3 ' end of the nucleic acid component free.
  • the peptide component can be designed to be cleavable by any chosen peptidase enzyme, of which many are known in the art. The nature of the peptidase is not particularly limited, it is necessary only for the peptidase to cleave somewhere in the peptide component. Similarly, the length and amino acid sequence of the peptide component is not particularly limited except by the need to be "cleavable" by the chosen peptidase.
  • the length and precise sequence of the nucleic acid component is also not particularly limited, it may be of any desired sequence. If the nucleic acid component is to function as a primer in solid-phase PCR, then its length and nucleotide sequence will be selected to enable annealing to the template to be amplified.
  • the product of the cleavage reaction may be subjected to denaturing conditions in order to remove the portion(s) of the cleaved strand(s) that are not attached to the solid support.
  • denaturing conditions will be apparent to the skilled reader with reference to standard molecular biology protocols (Sambrook et al., 2001, Molecular Cloning, A Laboratory Manual, 3rd Ed, Cold Spring Harbor Laboratory Press, Cold Spring Harbor Laboratory Press, NY; Current Protocols, eds Ausubel et al.) .
  • Denaturation results in the production of a sequencing template which is partially or substantially single- stranded.
  • a sequencing reaction may then be initiated by hybridisation of a sequencing primer to the single-stranded portion of the template.
  • the buffer additives and methods of the invention may be utilised in the nucleic acid sequencing methods described in WO 98/44152 and WO 00/18957, the contents of which are incorporated herein by reference. Both of these published International applications describe methods of parallel sequencing of multiple templates located at distinct locations on a solid support, and in particular sequencing of "clustered" arrays. The methods described therein, and indeed any other known method of sequencing nucleic acid clusters may be adapted according to the invention simply by including one or more antioxidants as additives in the buffer used for the detection/imaging steps.
  • antioxidant buffer additives in the detection steps has particular advantages in the context of sequencing on clustered arrays using fluorescently labelled nucleotide analogues. Nevertheless, the method of the invention may also be used in the context of sequencing templates on single molecule arrays of nucleic acid templates.
  • Single molecule arrays are generally formed by immobilisation of a single polynucleotide molecule at each discrete site that is detectable on the array.
  • Single- molecule arrays comprised of nucleic acid molecules that are individually resolvable by optical means and the use of such arrays in sequencing are described, for example, in WO 00/06770.
  • Single molecule arrays comprised of individually resolvable nucleic acid molecules including a hairpin loop structure are described in WO 01/57248.
  • the method of the invention is suitable for sequencing template molecules on single molecule arrays prepared according to the disclosures of WO 00/06770 or WO 01/57248.
  • the fluorescent moiety may be attached to a nucleic acid via any suitable covalent or non-covalent linkage.
  • the fluorescent moiety may be attached to an oligonucleotide primer or probe which is hybridised to a target nucleic acid molecule.
  • the invention provides a buffer for use in determining the identity of the base present in nucleotide (s) incorporated in a method of sequencing according to the first aspect of the invention or for use in detection of a fluorescent moiety incorporated in or attached to a polynucleotide molecule according to the second aspect of the invention, the buffer comprising one or more antioxidants in a concentration of at least 20 mM.
  • the buffers according to the invention will generally be of substantially similar composition to the detection/imaging buffer(s) typically used in the chosen detection/imaging technique, except for the addition of the antioxidant component (s) .
  • the buffer may contain other reaction components such as enzymes, enzyme cofactors, dNTPS etc if the presence of these components is compatible with the particular detection/imaging technique for which the buffer is intended to be used.
  • reaction buffer may be used for the nucleotide incorporation steps and for the detection steps, with no intermediate washing step.
  • the buffer may also comprise one or more nucleotides required for the nucleic synthesis reaction and also a suitable polymerase enzyme.
  • Buffers according to the invention can be supplied as liquid concentrates requiring dilution prior to use.
  • Buffers may also be supplied in the form of buffer tablets or solid "concentrates" to be dissolved in a suitable solvent prior to use in order to form the final buffer according to the invention. Such formats may be more convenient for supply. Buffer concentrates or tablets may be supplied together with instructions setting out how the buffer is to be diluted prior to use. In the case of buffer concentrates and buffer tablets the amount of antioxidant present in the buffer refers to the amount present in the final buffer as it is correctly diluted or made up prior to use.
  • the invention provides a kit for use in a method of sequencing according to the first aspect of the invention comprising: one or more nucleotides; an enzyme capable of catalysing incorporation of said nucleotides into a nucleic acid strand complementary to a nucleic acid template to be sequenced; and a buffer according to the present invention or a supply of antioxidant (s) suitable for preparing a buffer according to the present invention.
  • the nucleotide (s) will preferably be fluorescent labelled nucleotides, as described in connection with the method of the invention.
  • the nucleotides may be supplied in concentrated form for dilution prior to use and may be supplied in "reagent mixes" with other reaction components required for the sequencing reaction.
  • the enzyme may be any suitable enzyme capable of incorporating the chosen nucleotides into a nucleic acid strand.
  • suitable polymerase enzymes are known in the art and are available commercially.
  • the kit may include a modified polymerase as described in the applicant's co-pending International Patent Application PCT/ GB04/003891.
  • the buffer according to the invention may be conveniently supplied in the kit concentrated or solid form as described above. Alternatively, the kit may simply contain a concentrated supply of antioxidant (s) to be added into a suitable detection/imaging buffer supplied by the end user prior to use.
  • Figure 1 illustrates the sequence of a template DNA molecule with lambdaF fragment. The sequences and primer binding sites for the primers P7, P5 and #562 are also shown.
  • Figure 2 shows representative fluorescent images of clustered arrays on the 7th cycle of nucleotide incorporation using imaging buffer without ascorbate (3a) or with 5OmM ascorbate (3b) .
  • Solid-phase amplification was carried out in 8 channel glass chips such as those provided by Micronit (Twente, Nederland) or IMT (Neuchatel, Switzerland) coated with aminopropyltriethoxysilane derivatised with 1,3,5- benzenetriacetic acid (BTA) .
  • the experimental conditions and procedures are readily applicable to other solid supports.
  • Step 1 conversion of glass to amine-terminated glass
  • Step 3 conversion of amine-terminated glass to carboxylated glass
  • the 8 channel glass chips were pre-treated and silanized with 5% aminopropyltriethoxysilane, as described in the materials and methods of WO 00/18957 (incorporated herein by reference) .
  • BTA 1,3, 5-benzenetriacetic acid
  • NHS N-Hydroxysuccinimide
  • DCC dicyclohexylcarbodiimide
  • the silanized glass channels were carboxylated by treatment with the activated BTA ester then washed with DMF, ethanol, water, 5% NaHCO 3 pH8.8 and water.
  • the chips were dried under pure nitrogen and stored prior to use.
  • the BTA coated chips were grafted with P5 and P7 oligonucleotide primers in a 1:1 ratio.
  • the sequences of the P5 and P7 primers are as shown in Figure 1.
  • Grafting was carried out for 30 minutes at 50 0 C in a grafting solution (70 ⁇ l per channel) containing 0.5 ⁇ M of each primer, 10 mM carbodiimide and 10 mM 1-methyl-imadazol .
  • Clusters of immobilized DNA were formed by amplification on a solid support substantially as described in International patent application WO 00/18957. Amplification was carried out using a lambdaF template and primers P7 and P5 as shown in Figure 1.
  • thermocycled DNA colonies contains a disulfide group between the amino group necessary for the binding of the primer to the surface and its first nucleotide.
  • This disulfide bond in the P5 primer may be cleaved using Tris (2-carboxyethyl) -phosphate hydrochloride (TCEP) . Linearization was carried out at room temperature in a TCEP/Tris solution.
  • TCEP Tris (2-carboxyethyl) -phosphate hydrochloride
  • Templates to be linearised are typically exposed to
  • the procedure begins by a heating step in a stringent buffer (TE) to ensure complete denaturation of the colonies prior to hybridisation of the primer.
  • TE stringent buffer
  • Hybridization was carried out in 5x SSC, using an oligonucleotide diluted to a final concentration of 500 nM. This solution should be prepared just before use, especially when fluorophore-labelled oligonucleotides are used.
  • Typical temperature cycling profile is as follows: MJ-Research Thermocycler program set:
  • Oligo number 562 was hybridised to the linearised clusters prepared as described above at 50OnM. Nucleotide sequences of the template and primers are shown in Figure 1.
  • a mutant 9 0 N polymerase enzyme (an exo- variant including the triple mutation L408Y/Y409A/P410V and C223S) was used for the nucleotide incorporation steps.
  • Enzyme mix (enzymology buffer above plus 50 ⁇ g/ml YAV exo-
  • Templates were scanned in 4 colours.
  • non ascorbate buffer 100 mM Tris pH 7.0, 30 mM NaCl
  • ascorbate buffer 100 mM Tris pH 7.0, 30 mM NaCl, 50 mM sodium ascorbate
  • Enzymology buffer for 390 s 5xSSC buffer for 390 s
  • non ascorbate buffer (10OmM Tris pH 7.0, 3OmM NaCl) for 330 s, scan in 4 colours
  • DMSO buffer 100 mM Tris pH 7.0, 30 mM NaCl, 50 mM sodium ascorbate
  • the slides were scanned on a white light epifluorescence microscope set up with four separate excitation and emission channels appropriate to the fluorophores.
  • the solid supports used in this experiment were 8-channel glass chips such as those provided by Micronit (Twente, Nederland) or IMT (Neuchatel, Switzerland) . However, the experimental conditions and procedures are readily applicable to other solid supports.
  • Chips were washed as follows: neat Decon for 30 min, milliQ H 2 O for 30 min, NaOH IN for 15 min, milliQ H 2 O for 30 min, HCl 0.1N for 15 min, milliQ H 2 O for 30 min.
  • the 10 ml solution of acrylamide was first degassed with argon for 15 min.
  • the solutions of BRAPA, TEMED and potassium persulfate were successively added to the acrylamide solution.
  • the mixture was then quickly vortexed and immediately used.
  • Polymerization was then carried out for Ih 30 at RT. Afterwards the channels were washed with milliQ H 2 O for 30 min.
  • the slide are then dried by flushing argon through the inlets and stored under low pressure in a dessicator.
  • JV-Boc-l 5-diaminopentane toluene sulfonic acid was obtained from Novabiochem.
  • the primers were 5' -phosphorothioate oligonucleotides. Grafting was carried out using 80 ⁇ l per channel in 10 mM phosphate buffer pH7 for Ih at RT with the following two oligonucleotides each at a concentration of 0.5 ⁇ M.
  • P5 cleavable primer (supplied by ATD) :
  • the structure of the diol linker incorporated into the cleavable primer was as follows:
  • the channels are washed with 10 ttiM phosphate buffer, followed by 10 mM Tris/ 10 mM EDTA pH 8.0 (100 ⁇ L per channel) to remove unbound DNA.
  • An amplification template may be hybridised to the grafted primers immediately prior to the amplification reaction.
  • the amplification reaction thus begins with an initial primer extension step rather than template denaturation.
  • Amplification was carried out using a lambdaF template and primers P7 and P5 as shown in Figure 1.
  • the hybridization procedure begins with a heating step in a stringent buffer (95 0 C for 5 minutes in TE) to ensure complete denaturation prior to hybridisation of the template. Hybridization was then carried out in 5x SSC, using template diluted to the desired final concentration. After the hybridization, the chip was washed for 5 minutes with milliQ water to remove salts.
  • a typical program is as follows :
  • the first step in the amplification reaction was extension of the primers bound to template in the initial hybridisation step the first denaturation and annealing steps of this program are omitted (i.e. the chip is placed on the heating block only when the amplification mix is pumped through the flow cell and the temperature is at 73°C) .
  • the annealing temperature (X 0 C , step 2) depends on the primer pair that is used. Experiments have determined an optimal annealing temperature of 57°C for P5/P7 primers.
  • the optimum annealing temperature can be determined by experiment. The number of cycles may be varied if required.
  • Amplification was carried out in a reaction solution comprising Ix PCR reaction buffer (supplied with the enzyme) IM betain, 1.3% DMSO, 200 ⁇ M dNTPs and 0.025 U/ ⁇ L Taq polymerase.
  • Channels to be cleaved were treated with a solution of 0. IM of sodium periodate and 0. IM ethanolamine in water for 1 hour at room temperature. All channels were then washed for 30 minutes with milliQ water at room temperature.
  • the procedure begins with a heating step in a stringent buffer (TE) to ensure complete denaturation of the colonies prior to hybridisation of the primer.
  • TE stringent buffer
  • Hybridization was carried out in 5x SSC, using an oligonucleotide diluted to a final concentration of 500 nM.
  • Typical temperature cycling profile was as follows:
  • Oligo number 562 was hybridised to the linearised clusters prepared as described above at 50OnM. Nucleotide sequences of the template and primers are shown in Figure 1.
  • a mutant 9 0 N polymerase enzyme (an exo- variant including the triple mutation L408Y/Y409A/P410V and C223S) was used for the nucleotide incorporation steps.
  • Enzyme mix (enzymology buffer (50 mM Tris-HCl pH 8.0, 6 mM MgSO4, 1 mM EDTA, 0.05% (v/v) Tween -20) plus 50 ⁇ g/ml YAV exo- C223S, and l ⁇ M each of the four labelled modified nucleotides) was applied to the clustered templates, typically for 2 min 30s, and heated to 45°C.
  • Templates were maintained at 45°C for 30min, cooled to 20 0 C and washed for 5 min with enzymology buffer, then 5 min with 5x SSC. Templates were then exposed to one of two imaging buffers: "non-ascorbate buffer” (10OmM Tris pH7.0, 3OmM NaCl) , or ascorbate scan buffer (10OmM Tris pH7.0, 3OmM NaCl, 5OmM sodium ascorbate (freshly dissolved, filtered) .
  • non-ascorbate buffer (10OmM Tris pH7.0, 3OmM NaCl)
  • ascorbate scan buffer 10OmM Tris pH7.0, 3OmM NaCl, 5OmM sodium ascorbate (freshly dissolved, filtered) .
  • Templates were scanned in 4 colours. Templates were then exposed to cycles of TCEP treatment and enzymology as follows:
  • non ascorbate buffer 100 mM Tris pH 7.0, 30 mM NaCl
  • ascorbate buffer 100 mM Tris pH 7.0, 30 mM NaCl, 50 mM sodium ascorbate
  • non ascorbate buffer (10OmM Tris pH 7.0, 3OmM NaCl) for
  • DMSO buffer 100 mM Tris pH 7.0, 30 mM NaCl, 50 mM sodium ascorbate
  • the slides were scanned on a white light epifluorescence microscope set up with four separate excitation and emission channels appropriate to the fluorophores.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un additif pouvant être incorporé à des tampons utilisés dans des procédés de détection de nucléotides, et elle concerne des procédés améliorés de séquençage d'acides nucléiques utilisant cet additif, et en particulier l'utilisation de l'additif en question pour améliorer l'efficacité des réactions de séquençage d'acides nucléiques à cycles multiples reposant sur la fluorescence.
PCT/GB2005/004776 2004-12-13 2005-12-13 Procede ameliore de detection de nucleotides Ceased WO2006064199A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP05818529.9A EP1828412B2 (fr) 2004-12-13 2005-12-13 Procede ameliore de detection de nucleotides
US11/792,878 US9217178B2 (en) 2004-12-13 2005-12-13 Method of nucleotide detection
US14/295,039 US9303290B2 (en) 2004-12-13 2014-06-03 Method of nucleotide detection
US15/050,337 US9970055B2 (en) 2004-12-13 2016-02-22 Method of nucleotide detection

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0427236.5 2004-12-13
GBGB0427236.5A GB0427236D0 (en) 2004-12-13 2004-12-13 Improved method of nucleotide detection
GB0514933.1 2005-07-20
GBGB0514933.1A GB0514933D0 (en) 2004-12-13 2005-07-20 Improved method of nucleotide detection

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/792,878 A-371-Of-International US9217178B2 (en) 2004-12-13 2005-12-13 Method of nucleotide detection
US14/295,039 Continuation US9303290B2 (en) 2004-12-13 2014-06-03 Method of nucleotide detection

Publications (1)

Publication Number Publication Date
WO2006064199A1 true WO2006064199A1 (fr) 2006-06-22

Family

ID=36123236

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/004776 Ceased WO2006064199A1 (fr) 2004-12-13 2005-12-13 Procede ameliore de detection de nucleotides

Country Status (2)

Country Link
EP (1) EP1828412B2 (fr)
WO (1) WO2006064199A1 (fr)

Cited By (274)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062775A2 (fr) 2008-11-03 2010-06-03 The Regents Of The University Of California Procédés de détection d'acides nucléiques résistant à une modification
US7835871B2 (en) * 2007-01-26 2010-11-16 Illumina, Inc. Nucleic acid sequencing system and method
US8039817B2 (en) 2008-05-05 2011-10-18 Illumina, Inc. Compensator for multiple surface imaging
WO2012025250A1 (fr) 2010-08-27 2012-03-01 Illumina Cambridge Ltd. Méthodes de séquençage de polynucléotides
WO2012050920A1 (fr) 2010-09-29 2012-04-19 Illumina, Inc. Compositions et procédés de séquençage d'acides nucléiques
WO2012055929A1 (fr) 2010-10-26 2012-05-03 Illumina, Inc. Procédés de séquençage
WO2012058096A1 (fr) 2010-10-27 2012-05-03 Illumina, Inc. Microdispositifs et cartouches de biocapteurs pour analyse biologique ou chimique et systèmes et procédés associés
WO2012061036A1 (fr) 2010-11-03 2012-05-10 Illumina, Inc. Réduction de la formation de dimères adaptères
WO2012061832A1 (fr) 2010-11-05 2012-05-10 Illumina, Inc. Liaison entre des lectures de séquences à l'aide de codes marqueurs appariés
US8236532B2 (en) 2008-12-23 2012-08-07 Illumina, Inc. Multibase delivery for long reads in sequencing by synthesis protocols
WO2012106081A2 (fr) 2011-01-31 2012-08-09 Illumina, Inc. Procédés pour réduire les dommages occasionnés aux acides nucléiques
US20120208194A1 (en) * 2005-07-20 2012-08-16 Illumina Cambridge Limited Preparation of Templates for Nucleic Acid Sequencing
US8315817B2 (en) 2007-01-26 2012-11-20 Illumina, Inc. Independently removable nucleic acid sequencing system and method
WO2013049135A1 (fr) 2011-09-26 2013-04-04 Gen-Probe Incorporated Algorithmes de détermination de séquences
WO2013070627A2 (fr) 2011-11-07 2013-05-16 Illumina, Inc. Appareils de séquençage intégré et procédés d'utilisation
WO2013085710A2 (fr) 2011-12-09 2013-06-13 Illumina, Inc. Base de numération étendue pour étiquettes polymères
US8483969B2 (en) 2010-09-17 2013-07-09 Illuminia, Inc. Variation analysis for multiple templates on a solid support
WO2013117595A2 (fr) 2012-02-07 2013-08-15 Illumina Cambridge Limited Enrichissement et amplification ciblés d'acides nucléiques sur un support
WO2013131962A1 (fr) 2012-03-06 2013-09-12 Illumina Cambridge Limited Procédés améliorés de séquençage d'acides nucléiques
US8568979B2 (en) 2006-10-10 2013-10-29 Illumina, Inc. Compositions and methods for representational selection of nucleic acids from complex mixtures using hybridization
WO2014008448A1 (fr) 2012-07-03 2014-01-09 Sloan Kettering Institute For Cancer Research Évaluation quantitative de la reconstitution du répertoire des cellules t chez l'homme après une greffe allogénique de cellules souches hématopoïétiques
WO2014108810A2 (fr) 2013-01-09 2014-07-17 Lumina Cambridge Limited Préparation d'échantillon sur un support solide
WO2014116851A2 (fr) 2013-01-25 2014-07-31 Illumina, Inc. Procédés et systèmes pour utiliser un environnement informatique en nuage pour partager des données biologiques
WO2014142850A1 (fr) 2013-03-13 2014-09-18 Illumina, Inc. Procédés et compositions pour le séquençage d'acide nucléique
US8921073B2 (en) 2006-06-23 2014-12-30 Illumina, Inc. Devices and systems for creation of DNA cluster arrays
WO2015084985A2 (fr) 2013-12-03 2015-06-11 Illumina, Inc. Procédés et systèmes d'analyse de données d'image
WO2015103225A1 (fr) 2013-12-31 2015-07-09 Illumina, Inc. Cuve à circulation adressable utilisant des électrodes à motif
WO2015123444A2 (fr) 2014-02-13 2015-08-20 Illumina, Inc. Services génomiques au consommateur intégrés
US9115353B2 (en) 2011-01-31 2015-08-25 Illumina, Inc. Method for nucleotide detection
US9116139B2 (en) 2012-11-05 2015-08-25 Illumina, Inc. Sequence scheduling and sample distribution techniques
EP2918686A1 (fr) 2005-11-25 2015-09-16 Illumina Cambridge Limited Preparation de matrices d'acides nucleiques pour leur amplification en phase solide
WO2015175832A1 (fr) 2014-05-16 2015-11-19 Illumina, Inc. Techniques de synthèse d'acide nucléique
WO2015183871A1 (fr) 2014-05-27 2015-12-03 Illumina, Inc. Systèmes et procédés d'analyse biochimique comprenant un instrument de base et une cartouche amovible
US9284604B2 (en) 2010-11-22 2016-03-15 The Regents Of The University Of California Methods of identifying a cellular nascent RNA transcript
WO2016040602A1 (fr) 2014-09-11 2016-03-17 Epicentre Technologies Corporation Séquence au bisulfite à représentation réduite utilisant de l'uracile n-glycosylase (ung) et de l'endonucléase iv
WO2016061484A2 (fr) 2014-10-16 2016-04-21 Illumina, Inc. Systèmes de balayage optique pour analyse génétique in situ
WO2016073237A1 (fr) 2014-11-05 2016-05-12 Illumina Cambridge Limited Réduction des dommages sur l'adn pendant la préparation et le séquençage d'échantillons au moyen de chélateurs de sidérophores
US9376710B2 (en) 2004-01-07 2016-06-28 Illumina Cambridge Ltd. Methods of localizing nucleic acids to arrays
US9444880B2 (en) 2012-04-11 2016-09-13 Illumina, Inc. Cloud computing environment for biological data
WO2016196358A1 (fr) 2015-05-29 2016-12-08 Epicentre Technologies Corporation Méthodes d'analyse d'acides nucléiques
WO2017019456A2 (fr) 2015-07-27 2017-02-02 Illumina, Inc. Cartographie spatiale d'informations de séquence d'acide nucléique
WO2018018008A1 (fr) 2016-07-22 2018-01-25 Oregon Health & Science University Bibliothèques de génome entier de cellules uniques et procédés d'indexage combinatoire pour leur fabrication
WO2018057770A1 (fr) 2016-09-22 2018-03-29 Illumina, Inc. Détection de la variation du nombre de copies somatiques
EP3308860A1 (fr) 2016-10-14 2018-04-18 Illumina, Inc. Ensemble de cartouche
WO2018129314A1 (fr) 2017-01-06 2018-07-12 Illumina, Inc. Correction de phase
WO2018136118A1 (fr) 2017-01-20 2018-07-26 Omniome, Inc. Génotypage par liaison par polymérase
WO2018136117A1 (fr) 2017-01-20 2018-07-26 Omniome, Inc. Capture spécifique d'un allèle d'acides nucléiques
WO2018136416A1 (fr) 2017-01-17 2018-07-26 Illumina, Inc. Détermination de variant d'épissage oncogène
EP3373174A1 (fr) 2006-03-31 2018-09-12 Illumina, Inc. Systèmes et procédés pour analyse de séquençage par synthèse
WO2018175798A1 (fr) 2017-03-24 2018-09-27 Life Technologies Corporation Adaptateurs polynucléotidiques et procédés d'utilisation de ces derniers
WO2018197945A1 (fr) 2017-04-23 2018-11-01 Illumina Cambridge Limited Compositions et procédés permettant d'améliorer l'identification d'échantillons dans des bibliothèques d'acides nucléiques indexés
WO2018200386A1 (fr) 2017-04-23 2018-11-01 Illumina, Inc. Compositions et procédés pour améliorer l'identification d'échantillons dans des bibliothèques d'acides nucléiques indexés
WO2018200380A1 (fr) 2017-04-23 2018-11-01 Illumina, Inc. Compositions et procédés d'amélioration de l'identification d'échantillons dans des bibliothèques indexées d'acides nucléiques
WO2018197950A1 (fr) 2017-04-23 2018-11-01 Illumina Cambridge Limited Compositions et procédés pour améliorer l'identification d'échantillons dans des bibliothèques d'acides nucléiques indexées
WO2018204423A1 (fr) 2017-05-01 2018-11-08 Illumina, Inc. Séquences index optimales pour séquençage multiplex massivement parallèle
WO2018208699A1 (fr) 2017-05-08 2018-11-15 Illumina, Inc. Courts adaptateurs universels pour l'indexage d'échantillons de polynucléotides
WO2018213803A1 (fr) 2017-05-19 2018-11-22 Neon Therapeutics, Inc. Identification de néo-antigène immunogène
WO2018226708A1 (fr) 2017-06-07 2018-12-13 Oregon Health & Science University Banques de génomes entiers de cellules individuelles pour le séquençage de méthylation
WO2018236631A1 (fr) 2017-06-20 2018-12-27 Illumina, Inc. Procédés et compositions pour résoudre les inefficacités dans des réactions d'amplification
WO2019028047A1 (fr) 2017-08-01 2019-02-07 Illumina, Inc Indexation spatiale de matériel génétique et préparation de pharmacothèque à l'aide de billes d'hydrogel et de cellules d'écoulement
WO2019027767A1 (fr) 2017-07-31 2019-02-07 Illumina Inc. Système de séquençage comportant une agrégation d'échantillons biologiques multiplexés
WO2019023924A1 (fr) 2017-08-01 2019-02-07 Helitec Limited Procédés d'enrichissement et de détermination de séquences nucléotidiques cibles
WO2019055715A1 (fr) 2017-09-15 2019-03-21 Illumina, Inc. Adaptateurs courts universels à identifiants moléculaires uniques non aléatoires de longueur variable
US10253352B2 (en) 2015-11-17 2019-04-09 Omniome, Inc. Methods for determining sequence profiles
WO2019090251A2 (fr) 2017-11-06 2019-05-09 Illumina, Inc. Techniques d'indexation d'acide nucléique
WO2019099529A1 (fr) 2017-11-16 2019-05-23 Illumina, Inc. Systèmes et procédés de détermination d'une instabilité de microsatellite
WO2019108972A1 (fr) 2017-11-30 2019-06-06 Illumina, Inc. Procédés et systèmes de validation pour appels de variantes de séquences
WO2019136376A1 (fr) 2018-01-08 2019-07-11 Illumina, Inc. Séquençage à haut débit à détection à semi-conducteur
WO2019195225A1 (fr) 2018-04-02 2019-10-10 Illumina, Inc. Compositions et procédés de préparation de témoins pour un test génétique basé sur une séquence
US10450598B2 (en) 2015-09-11 2019-10-22 Illumina, Inc. Systems and methods for obtaining a droplet having a designated concentration of a substance-of-interest
WO2019222688A1 (fr) 2018-05-17 2019-11-21 Illumina, Inc. Séquençage de cellules uniques à haut débit avec biais d'amplification réduit
US10486153B2 (en) 2013-09-27 2019-11-26 Illumina, Inc. Method to produce chemical pattern in micro-fluidic structure
US10540783B2 (en) 2013-11-01 2020-01-21 Illumina, Inc. Image analysis useful for patterned objects
WO2020036991A1 (fr) 2018-08-15 2020-02-20 Illumina, Inc. Compositions et procédés pour améliorer l'enrichissement de bibliothèques
US10576471B2 (en) 2015-03-20 2020-03-03 Illumina, Inc. Fluidics cartridge for use in the vertical or substantially vertical position
WO2020047007A2 (fr) 2018-08-28 2020-03-05 10X Genomics, Inc. Procédés de génération de matrices à codes-barres spatiaux
WO2020047005A1 (fr) 2018-08-28 2020-03-05 10X Genomics, Inc. Résolution de réseaux spatiaux
US10590464B2 (en) 2015-05-29 2020-03-17 Illumina Cambridge Limited Enhanced utilization of surface primers in clusters
US10619204B2 (en) 2014-11-11 2020-04-14 Illumina Cambridge Limited Methods and arrays for producing and sequencing monoclonal clusters of nucleic acid
WO2020104851A1 (fr) 2018-11-21 2020-05-28 Akershus Universitetssykehus Hf Séquençage d'enrichissement de pcr multiplex associé à une tagmentation
WO2020114918A1 (fr) 2018-12-05 2020-06-11 Illumina Cambridge Limited Procédés et compositions pour la génération de grappes par amplification en pont
WO2020120179A1 (fr) 2018-12-14 2020-06-18 Illumina Cambridge Limited Réduction du phasage avec des nucléotides non marqués pendant le séquençage
WO2020123318A1 (fr) 2018-12-10 2020-06-18 10X Genomics, Inc. Résolution de réseaux spatiaux à l'aide d'une déconvolution
EP3670672A1 (fr) 2006-10-06 2020-06-24 Illumina Cambridge Limited Procédé de séquençage d'un modèle de polynucléotide
WO2020126602A1 (fr) 2018-12-18 2020-06-25 Illumina Cambridge Limited Procédés et compositions pour séquençage d'extrémités appariées à l'aide d'une amorce de surface unique
WO2020126593A1 (fr) 2018-12-17 2020-06-25 Illumina Cambridge Limited Compositions destinées à être utilisées dans le séquençage de polynucléotides
WO2020126595A1 (fr) 2018-12-17 2020-06-25 Illumina Cambridge Limited Oligonucléotide d'amorce pour le séquençage
WO2020132103A1 (fr) 2018-12-19 2020-06-25 Illumina, Inc. Procédés d'amélioration de la priorité de la clonalité d'un ensemble de polynucléotides
EP3698874A1 (fr) 2014-03-11 2020-08-26 Illumina, Inc. Cartouche microfluidique intégrée et jetable et leurs procédés de fabrication
EP3699289A1 (fr) 2014-06-09 2020-08-26 Illumina Cambridge Limited Préparation d'échantillons pour l'amplification d'acide nucléique
WO2020176788A1 (fr) 2019-02-28 2020-09-03 10X Genomics, Inc. Profilage d'analytes biologiques avec des réseaux d'oligonucléotides à codes-barres spatiaux
WO2020180778A1 (fr) 2019-03-01 2020-09-10 Illumina, Inc. Banques de noyaux uniques et à cellule unique à haut rendement et leurs procédés de production et d'utilisation
WO2020190509A1 (fr) 2019-03-15 2020-09-24 10X Genomics, Inc. Méthodes d'utilisation de matrices spatiales pour le séquençage d'organismes unicellulaires
WO2020191389A1 (fr) 2019-03-21 2020-09-24 Illumina, Inc. Génération de données d'apprentissage pour séquençage à base d'intelligence artificielle
NL2023314B1 (en) 2019-03-21 2020-09-28 Illumina Inc Artificial intelligence-based quality scoring
NL2023316B1 (en) 2019-03-21 2020-09-28 Illumina Inc Artificial intelligence-based sequencing
NL2023310B1 (en) 2019-03-21 2020-09-28 Illumina Inc Training data generation for artificial intelligence-based sequencing
NL2023311B1 (en) 2019-03-21 2020-09-28 Illumina Inc Artificial intelligence-based generation of sequencing metadata
NL2023312B1 (en) 2019-03-21 2020-09-28 Illumina Inc Artificial intelligence-based base calling
WO2020198071A1 (fr) 2019-03-22 2020-10-01 10X Genomics, Inc. Analyse spatiale tridimensionnelle
EP3725893A1 (fr) 2015-02-10 2020-10-21 Illumina, Inc. Compositions pour l'analyse de composants cellulaires
US10844428B2 (en) 2015-04-28 2020-11-24 Illumina, Inc. Error suppression in sequenced DNA fragments using redundant reads with unique molecular indices (UMIS)
US10844429B2 (en) 2017-01-18 2020-11-24 Illumina, Inc. Methods and systems for generation and error-correction of unique molecular index sets with heterogeneous molecular lengths
WO2020243579A1 (fr) 2019-05-30 2020-12-03 10X Genomics, Inc. Procédés de détection de l'hétérogénéité spatiale d'un échantillon biologique
WO2021008805A1 (fr) 2019-07-12 2021-01-21 Illumina Cambridge Limited Compositions et procédés de préparation de bibliothèques de séquençage d'acide nucléique à l'aide de crispr/cas9 immobilisé sur un support solide
EP3783109A1 (fr) 2015-03-31 2021-02-24 Illumina Cambridge Limited Surface de concamerisation de matrices
EP3798319A1 (fr) 2019-09-30 2021-03-31 Diagenode S.A. Procédé de diagnostic et/ou de séquençage amélioré et kit
US10976334B2 (en) 2015-08-24 2021-04-13 Illumina, Inc. In-line pressure accumulator and flow-control system for biological or chemical assays
WO2021091611A1 (fr) 2019-11-08 2021-05-14 10X Genomics, Inc. Agents de capture d'analytes marqués spatialement pour le multiplexage d'analytes
WO2021102039A1 (fr) 2019-11-21 2021-05-27 10X Genomics, Inc, Analyse spatiale d'analytes
EP3828283A1 (fr) 2019-11-28 2021-06-02 Diagenode S.A. Procédé et kit de séquençage améliorés
WO2021127436A2 (fr) 2019-12-19 2021-06-24 Illumina, Inc. Banques de cellules uniques à haut débit et leurs procédés de production et d'utilisation
WO2021123074A1 (fr) 2019-12-18 2021-06-24 F. Hoffmann-La Roche Ag Procédés de séquençage par synthèse au moyen d'un schéma de marquage consécutif
EP3854884A1 (fr) 2015-08-14 2021-07-28 Illumina, Inc. Systèmes et procédés mettant en oeuvre des capteurs à sensibilité magnétique pour la détermination d'une caractéristique génétique
US11098356B2 (en) 2008-01-28 2021-08-24 Complete Genomics, Inc. Methods and compositions for nucleic acid sequencing
WO2021168287A1 (fr) 2020-02-21 2021-08-26 10X Genomics, Inc. Méthodes et compositions pour dosage spatial in situ intégré
WO2021168018A1 (fr) 2020-02-20 2021-08-26 Illumina, Inc. Exécution et accélération matérielle d'un appelant de base à base d'intelligence artificielle
EP3878974A1 (fr) 2015-07-06 2021-09-15 Illumina Cambridge Limited Préparation d'échantillons pour l'amplification d'acide nucléique
US11156603B2 (en) 2010-04-05 2021-10-26 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11162132B2 (en) 2015-04-10 2021-11-02 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
WO2021226522A1 (fr) 2020-05-08 2021-11-11 Illumina, Inc. Techniques de séquençage et de détection de génome
EP3910069A1 (fr) 2014-02-18 2021-11-17 Illumina, Inc. Procédés et composition de profilage d'adn
WO2021231477A2 (fr) 2020-05-12 2021-11-18 Illumina, Inc. Génération d'acides nucléiques avec des bases modifiées au moyen de désoxynucléotidyl transférase terminale recombinante
US11181478B2 (en) 2013-12-10 2021-11-23 Illumina, Inc. Biosensors for biological or chemical analysis and methods of manufacturing the same
EP3913358A1 (fr) 2018-01-08 2021-11-24 Illumina Inc Séquençage à haut débit à détection à semi-conducteur
WO2021252617A1 (fr) 2020-06-09 2021-12-16 Illumina, Inc. Procédés pour augmenter le rendement de bibliothèques de séquençage
WO2021252375A1 (fr) 2020-06-08 2021-12-16 The Broad Institute, Inc. Indexation combinatoire à cellule unique, à partir d'acides nucléiques amplifiés
US11208684B2 (en) 2010-04-05 2021-12-28 Prognosys Biosciences, Inc. Spatially encoded biological assays
WO2022006081A1 (fr) 2020-06-30 2022-01-06 Illumina, Inc. Séquençage à commande catalytique par synthèse pour produire de l'adn sans scarification
WO2022010965A1 (fr) 2020-07-08 2022-01-13 Illumina, Inc. Billes utilisées en tant que supports pour transposomes
EP3940083A1 (fr) 2015-10-07 2022-01-19 Illumina, Inc. Réduction de capture hors cible dans des techniques de séquençage
US11286515B2 (en) 2013-06-25 2022-03-29 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
EP3974538A1 (fr) 2014-11-05 2022-03-30 Illumina Cambridge Limited Séquençage à partir de multiples amorces pour accroître le débit et la densité des données
US11352659B2 (en) 2011-04-13 2022-06-07 Spatial Transcriptomics Ab Methods of detecting analytes
WO2022119812A1 (fr) 2020-12-02 2022-06-09 Illumina Software, Inc. Système et procédé pour la détection d'altérations génétiques
WO2022164809A1 (fr) 2021-01-26 2022-08-04 10X Genomics, Inc. Sondes analogiques d'acide nucléique pour analyse in situ
WO2022197752A1 (fr) 2021-03-16 2022-09-22 Illumina, Inc. Sélection d'ensembles de poids basée sur l'emplacement d'un élément et/ou le cycle pour appel de base
WO2022204032A1 (fr) 2021-03-22 2022-09-29 Illumina Cambridge Limited Procédés d'amélioration de la clonalité de groupes d'acides nucléiques
US11458469B2 (en) 2016-10-14 2022-10-04 Illumina, Inc. Cartridge assembly
WO2022207804A1 (fr) 2021-03-31 2022-10-06 Illumina Cambridge Limited Techniques de séquençage de bibliothèque d'acides nucléiques avec détection de dimères adaptateurs
WO2022213027A1 (fr) 2021-04-02 2022-10-06 Illumina, Inc. Modèle d'apprentissage automatique pour la détection d'une bulle dans une lame d'échantillon de nucléotide pour séquençage
FR3121936A1 (fr) 2021-04-20 2022-10-21 Naos Institute Of Life Science Methode de criblage d’ingredients et de compositions topiques ecobiologiques, et son utilisation pour realiser un soin cosmetique de restauration du microbiote cutane
WO2022232425A2 (fr) 2021-04-29 2022-11-03 Illumina, Inc. Techniques d'amplification pour la caractérisation d'acides nucléiques
US11515010B2 (en) 2021-04-15 2022-11-29 Illumina, Inc. Deep convolutional neural networks to predict variant pathogenicity using three-dimensional (3D) protein structures
US11514575B2 (en) 2019-10-01 2022-11-29 10X Genomics, Inc. Systems and methods for identifying morphological patterns in tissue samples
WO2022251510A2 (fr) 2021-05-28 2022-12-01 Illumina, Inc. Analogues de nucléotides oligo-modifiés pour la préparation d'acides nucléiques
US11519033B2 (en) 2018-08-28 2022-12-06 10X Genomics, Inc. Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample
WO2022256229A1 (fr) 2021-06-03 2022-12-08 Illumina Cambridge Limited Systèmes et procédés de séquençage de nucléotides à l'aide de deux canaux optiques
WO2022271954A1 (fr) 2021-06-24 2022-12-29 Illumina, Inc. Procédés et compositions pour l'indexation combinatoire d'acides nucléiques à base de billes
WO2022272260A1 (fr) 2021-06-23 2022-12-29 Illumina, Inc. Compositions, procédés, kits, cartouches et systèmes de séquençage de réactifs
WO2023278609A1 (fr) 2021-06-29 2023-01-05 Illumina, Inc. Appelant de base auto-appris, entraîné à l'aide de séquences d'organismes
WO2023278927A1 (fr) 2021-06-29 2023-01-05 Illumina Software, Inc. Métrique de rapport signal-sur-bruit pour déterminer des identifications de bases nucléotidiques et qualité d'identification de bases
WO2023278788A1 (fr) 2021-07-01 2023-01-05 Illumina, Inc. Appel de base reposant sur l'intelligence artificielle efficace de séquences d'index
WO2023278184A1 (fr) 2021-06-29 2023-01-05 Illumina, Inc. Procédés et systèmes pour corriger une diaphonie dans un éclairage émis par des sites de réaction
WO2023278966A1 (fr) 2021-06-29 2023-01-05 Illumina, Inc. Modèle d'apprentissage automatique pour générer des classifications de confiance pour des coordonnées génomiques
WO2023287617A1 (fr) 2021-07-13 2023-01-19 Illumina, Inc. Procédés et systèmes pour l'extraction en temps réel de diaphonie dans un éclairage émis à partir de sites de réaction
WO2023004323A1 (fr) 2021-07-23 2023-01-26 Illumina Software, Inc. Modèle d'apprentissage automatique pour réétalonner des appels de base de nucléotides
WO2023003757A1 (fr) 2021-07-19 2023-01-26 Illumina Software, Inc. Extraction d'intensité avec interpolation et adaptation pour appel de base
WO2023009758A1 (fr) 2021-07-28 2023-02-02 Illumina, Inc. Étalonnage de score de qualité de systèmes d'appel de bases
WO2023014741A1 (fr) 2021-08-03 2023-02-09 Illumina Software, Inc. Assignation de bases utilisant de multiples modèles de systèmes d'assignation de bases
US11593649B2 (en) 2019-05-16 2023-02-28 Illumina, Inc. Base calling using convolutions
WO2023034079A1 (fr) 2021-09-01 2023-03-09 Illumina Software, Inc. Modulation d'amplitude pour identification de base accélérée
WO2023035110A1 (fr) * 2021-09-07 2023-03-16 深圳华大智造科技股份有限公司 Procédé d'analyse de séquence de polynucléotide cible
WO2023035108A1 (fr) * 2021-09-07 2023-03-16 深圳华大智造科技股份有限公司 Procédé d'analyse de la séquence d'un polynucléotide cible
WO2023044229A1 (fr) 2021-09-17 2023-03-23 Illumina, Inc. Identification automatique de sources de défaillance en séquençage nucléotidique à partir de motifs d'erreur d'appel de base
WO2023049558A1 (fr) 2021-09-21 2023-03-30 Illumina, Inc. Génome de référence de graphe et stratégie d'appel de bases utilisant des haplotypes attribués
WO2023052427A1 (fr) 2021-09-30 2023-04-06 Illumina Cambridge Limited Séquençage de polynucléotides
US11649485B2 (en) 2019-01-06 2023-05-16 10X Genomics, Inc. Generating capture probes for spatial analysis
WO2023102354A1 (fr) 2021-12-02 2023-06-08 Illumina Software, Inc. Génération de corrections de signal spécifique à un groupe pour déterminer des appels de base nucléotidique
WO2023102118A2 (fr) 2021-12-01 2023-06-08 10X Genomics, Inc. Procédés, compositions et systèmes pour la détection améliorée d'analytes in situ et analyse spatiale
US11676685B2 (en) 2019-03-21 2023-06-13 Illumina, Inc. Artificial intelligence-based quality scoring
WO2023107622A1 (fr) 2021-12-10 2023-06-15 Illumina, Inc. Séquençage d'échantillons et d'indices parallèles
WO2023122362A1 (fr) 2021-12-23 2023-06-29 Illumina Software, Inc. Facilitation de l'exécution sécurisée de flux de travail externes pour des diagnostics de séquençage génomique
WO2023122363A1 (fr) 2021-12-23 2023-06-29 Illumina Software, Inc. Résumés dynamiques d'état graphique pour séquençage de nucléotides
WO2023129764A1 (fr) 2021-12-29 2023-07-06 Illumina Software, Inc. Permutation automatique des versions de modèle d'analyse de variants pour les applications d'analyse génomique
WO2023129896A1 (fr) 2021-12-28 2023-07-06 Illumina Software, Inc. Modèle d'apprentissage automatique pour réétalonner des appels de base nucléotidiques correspondant à des variants cibles
WO2023126457A1 (fr) 2021-12-29 2023-07-06 Illumina Cambridge Ltd. Procédés de séquençage d'acide nucléique à l'aide d'amorces liées à une surface
US11733238B2 (en) 2010-04-05 2023-08-22 Prognosys Biosciences, Inc. Spatially encoded biological assays
WO2023164492A1 (fr) 2022-02-25 2023-08-31 Illumina, Inc. Modèles d'apprentissage automatique destinés à détecter et ajuster des valeurs pour des niveaux de méthylation de nucléotides
WO2023164660A1 (fr) 2022-02-25 2023-08-31 Illumina, Inc. Séquences d'étalonnage à des fins de séquençage de nucléotide
US11749380B2 (en) 2020-02-20 2023-09-05 Illumina, Inc. Artificial intelligence-based many-to-many base calling
WO2023175024A1 (fr) 2022-03-15 2023-09-21 Illumina, Inc. Séquençage d'extrémité appariée
WO2023192616A1 (fr) 2022-04-01 2023-10-05 10X Genomics, Inc. Compositions et procédés de masquage ciblé d'autofluorescence
WO2023196526A1 (fr) 2022-04-06 2023-10-12 10X Genomics, Inc. Procédés d'analyse multiplex de cellules
WO2023196528A1 (fr) 2022-04-08 2023-10-12 Illumina, Inc. Techniques de détection et de compression de plage dynamique d'aptamères
WO2023196572A1 (fr) 2022-04-07 2023-10-12 Illumina Singapore Pte. Ltd. Cytidine désaminases modifiées et méthodes d'utilisation
EP4269618A2 (fr) 2018-06-04 2023-11-01 Illumina, Inc. Procédés de production des bibliothèques de transcriptomes à une seule cellule à haut débit et leurs
WO2023212601A1 (fr) 2022-04-26 2023-11-02 Illumina, Inc. Modèles d'apprentissage automatique pour sélectionner des sondes oligonucléotidiques pour des technologies de réseau
WO2023209606A1 (fr) 2022-04-29 2023-11-02 Illumina Cambridge Limited Procédés et systèmes d'encapsulation de microsphères lyophilisées
WO2023215612A1 (fr) 2022-05-06 2023-11-09 10X Genomics, Inc. Analyse d'un antigène et des interactions antigène-récepteur
EP4276769A2 (fr) 2019-03-21 2023-11-15 Illumina, Inc. Génération de données d'apprentissage pour séquençage à base d'intelligence artificielle
WO2023220627A1 (fr) 2022-05-10 2023-11-16 Illumina Software, Inc. Réseau neuronal adaptatif pour séquençage de nucléotides
WO2023225095A1 (fr) 2022-05-18 2023-11-23 Illumina Cambridge Limited Préparation de fragments d'acide nucléique à taille contrôlée
WO2023250504A1 (fr) 2022-06-24 2023-12-28 Illumina Software, Inc. Amélioration d'alignement de lecture de division en identifiant et en évaluant de manière intelligente des groupes de divisions candidats
WO2024006705A1 (fr) 2022-06-27 2024-01-04 Illumina Software, Inc. Génotypage amélioré d'antigène leucocytaire humain (hla)
WO2024006769A1 (fr) 2022-06-27 2024-01-04 Illumina Software, Inc. Génération et mise en œuvre d'un génome à graphe de variation structurelle
WO2024006779A1 (fr) 2022-06-27 2024-01-04 Illumina, Inc. Accélérateurs pour un modèle d'imputation de génotypes
US11866780B2 (en) * 2008-10-02 2024-01-09 Illumina Cambridge Limited Nucleic acid sample enrichment for sequencing applications
WO2024026356A1 (fr) 2022-07-26 2024-02-01 Illumina, Inc. Traitement multiomique à cellule unique rapide à l'aide d'un fichier exécutable
US11926867B2 (en) 2019-01-06 2024-03-12 10X Genomics, Inc. Generating capture probes for spatial analysis
WO2024050820A1 (fr) * 2022-09-09 2024-03-14 深圳华大智造科技股份有限公司 Composition antioxydante et son utilisation dans la détection d'acides nucléiques
WO2024059852A1 (fr) 2022-09-16 2024-03-21 Illumina, Inc. Segmentation de grappes et appel de bases conditionnel
US11940413B2 (en) 2007-02-05 2024-03-26 IsoPlexis Corporation Methods and devices for sequencing nucleic acids in smaller batches
WO2024069581A1 (fr) 2022-09-30 2024-04-04 Illumina Singapore Pte. Ltd. Complexes hélicase-cytidine désaminase et procédés d'utilisation
WO2024073516A1 (fr) 2022-09-29 2024-04-04 Illumina, Inc. Panneau de référence de variant cible servant à imputer des variants cibles
WO2024073043A1 (fr) 2022-09-30 2024-04-04 Illumina, Inc. Procédés d'utilisation de protéines de liaison cpg dans la cartographie de nucléotides cytosine modifiés
WO2024073047A1 (fr) 2022-09-30 2024-04-04 Illumina, Inc. Cytidine désaminases et procédés d'utilisation dans la cartographie de nucléotides cytosine modifiés
WO2024073519A1 (fr) 2022-09-30 2024-04-04 Illumina, Inc. Modèle d'apprentissage automatique pour affiner des appels de variants structuraux
WO2024077096A1 (fr) 2022-10-05 2024-04-11 Illumina, Inc. Intégration d'appels de variants à partir de multiples pipelines de séquençage à l'aide d'une architecture d'apprentissage automatique
WO2024081649A1 (fr) 2022-10-11 2024-04-18 Illumina, Inc. Détection et correction de valeurs de méthylation à partir de dosages de séquençage de méthylation
WO2024118791A1 (fr) 2022-11-30 2024-06-06 Illumina, Inc. Prédiction précise de variants à partir de données de séquençage de méthylation
WO2024118903A1 (fr) 2022-11-30 2024-06-06 Illumina, Inc. Correction chimio-enzymatique de transformations d'uracile faux positives
WO2024137886A1 (fr) 2022-12-21 2024-06-27 Illumina, Inc. Appel de base dépendant du contexte
WO2024147904A1 (fr) 2023-01-06 2024-07-11 Illumina, Inc. Réduction des uraciles par polymérase
USRE50065E1 (en) 2012-10-17 2024-07-30 10X Genomics Sweden Ab Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
WO2024167954A1 (fr) 2023-02-06 2024-08-15 Illumina, Inc. Détermination et élimination d'interférence de lumière inter-groupes
US12071667B2 (en) 2020-11-04 2024-08-27 10X Genomics, Inc. Sequence analysis using meta-stable nucleic acid molecules
US12083514B2 (en) 2018-07-03 2024-09-10 Illumina, Inc. Interposer with first and second adhesive layers
WO2024191806A1 (fr) 2023-03-10 2024-09-19 Illumina, Inc. Techniques de détection d'aptamères
US12106828B2 (en) 2019-05-16 2024-10-01 Illumina, Inc. Systems and devices for signal corrections in pixel-based sequencing
WO2024206848A1 (fr) 2023-03-30 2024-10-03 Illumina, Inc. Génotypage à répétition en tandem
US12112833B2 (en) 2020-02-04 2024-10-08 10X Genomics, Inc. Systems and methods for index hopping filtering
US12110541B2 (en) 2020-02-03 2024-10-08 10X Genomics, Inc. Methods for preparing high-resolution spatial arrays
WO2024229396A1 (fr) 2023-05-03 2024-11-07 Illumina, Inc. Modèle d'apprentissage automatique pour réétalonner des appels de génotype à partir de fichiers de données de séquençage existants
US12154266B2 (en) 2019-11-18 2024-11-26 10X Genomics, Inc. Systems and methods for binary tissue classification
US12151241B2 (en) 2011-01-10 2024-11-26 Illumina, Inc. Systems, methods, and apparatuses to image a sample for biological or chemical analysis
WO2024249591A1 (fr) 2023-05-31 2024-12-05 Illumina, Inc. Procédés de séquençage double brin par synthèse
WO2024249466A1 (fr) 2023-05-31 2024-12-05 Illumina, Inc. Réduction de faux positifs par réparation de polymérase par translésion
WO2024249973A2 (fr) 2023-06-02 2024-12-05 Illumina, Inc. Liaison de gènes humains à des phénotypes cliniques à l'aide de réseaux neuronaux graphiques
WO2024249200A1 (fr) 2023-05-26 2024-12-05 Illumina, Inc. Procédés de conservation de l'état de méthylation pendant le regroupement
WO2024249940A1 (fr) 2023-05-31 2024-12-05 Illumina, Inc. Amélioration d'un alignement de variants structuraux et appel de variant à l'aide d'un génome de référence de variant structural
US12168801B1 (en) 2020-07-02 2024-12-17 10X Genomics, Inc. Hybrid/capture probe designs for full-length cDNA
WO2025006466A1 (fr) 2023-06-30 2025-01-02 Illumina, Inc. Systèmes et procédés de séquençage de polynucléotides avec quatre nucléotides marqués
WO2025006565A1 (fr) 2023-06-27 2025-01-02 Illumina, Inc. Appel de variant avec estimation du niveau de méthylation
WO2025006464A1 (fr) 2023-06-30 2025-01-02 Illumina, Inc. Systèmes et procédés de séquençage de polynucléotides avec des diagrammes de dispersion alternatifs
WO2025006874A1 (fr) 2023-06-30 2025-01-02 Illumina, Inc. Modèle d'apprentissage automatique pour réétalonner des appels de génotype correspondant à des variants de lignée germinale et variants de mosaïque somatique
WO2025006460A1 (fr) 2023-06-30 2025-01-02 Illumina, Inc. Systèmes et procédés de séquençage de polynucléotides à bases modifiées
US12188085B2 (en) 2020-03-05 2025-01-07 10X Genomics, Inc. Three-dimensional spatial transcriptomics with sequencing readout
US12215379B2 (en) 2020-02-17 2025-02-04 10X Genomics, Inc. In situ analysis of chromatin interaction
US12227798B2 (en) 2008-03-19 2025-02-18 IsoPlexis Corporation Methods and compositions for incorporating nucleotides
WO2025049331A2 (fr) 2023-08-31 2025-03-06 Illumina, Inc. Techniques de détection d'aptamères
WO2025049720A2 (fr) 2023-08-31 2025-03-06 Illumina, Inc. Techniques de détection et de compression de plage dynamique d'aptamères
EP4520821A1 (fr) 2023-09-08 2025-03-12 The Regents Of The University Of Michigan Arn et polypeptides dérivés de microarn et leurs utilisations
WO2025054389A1 (fr) 2023-09-07 2025-03-13 Illumina, Inc. Identification de la cytosine méthylée par l'utilisation de points de repère
WO2025061922A1 (fr) 2023-09-20 2025-03-27 Illumina, Inc. Procédés de séquençage
WO2025061942A1 (fr) 2023-09-20 2025-03-27 Illumina, Inc. Identification et correction d'erreur de séquençage
WO2025072870A1 (fr) 2023-09-29 2025-04-03 Illumina, Inc. Suivi et modification d'emplacement de cluster sur des lames d'échantillon de nucléotides en temps réel
WO2025072793A1 (fr) 2023-09-28 2025-04-03 Illumina, Inc. Cytidine désaminases modifiées et procédés d'utilisation
WO2025072833A1 (fr) 2023-09-29 2025-04-03 Illumina, Inc. Prédiction de longueurs d'insert à l'aide de métriques d'analyse primaire
WO2025081064A2 (fr) 2023-10-11 2025-04-17 Illumina, Inc. Désaminase thermophile et procédés d'identification de cytosine modifiée
WO2025090883A1 (fr) 2023-10-27 2025-05-01 Illumina, Inc. Détection de variants dans des séquences nucléotidiques sur la base d'une diversité d'haplotype
WO2025117738A1 (fr) 2023-11-28 2025-06-05 Illumina, Inc. Procédés d'amélioration d'efficacité de ligature d'indice moléculaire unique
WO2025123005A2 (fr) 2023-12-07 2025-06-12 Illumina, Inc. Préparation et compositions d'acide nucléique cot-1
WO2025129133A1 (fr) 2023-12-15 2025-06-19 Illumina, Inc. Modèles de maladie résiduelle minime (mrd) pour déterminer des probabilités qu'un sujet comprenne un cancer
WO2025136998A1 (fr) 2023-12-18 2025-06-26 Illumina, Inc. Utilisation de modèles d'apprentissage automatique pour détecter une maladie résiduelle minimale (mrd) chez un sujet
WO2025137222A1 (fr) 2023-12-19 2025-06-26 Illumina, Inc. Dosage de détection de méthylation
WO2025137341A1 (fr) 2023-12-20 2025-06-26 Illumina, Inc. Détermination directe de mesures de rapport signal sur bruit pour une convergence accélérée lors de la détermination d'appels de base nucléotidique et d'une qualité d'appel de base
WO2025137647A1 (fr) 2023-12-21 2025-06-26 Illumina, Inc. Mappage et alignement améliorés de lectures de nucléotides à l'aide d'une structure de données d'haplotype améliorée avec des différences allèle-variant
WO2025144626A1 (fr) 2023-12-28 2025-07-03 Illumina, Inc. Séquençage avec protéines de liaison simple brin
US12354008B2 (en) 2020-02-20 2025-07-08 Illumina, Inc. Knowledge distillation and gradient pruning-based compression of artificial intelligence-based base caller
WO2025160089A1 (fr) 2024-01-26 2025-07-31 Illumina, Inc. Construction de référence multigénome personnalisée pour une analyse de séquençage améliorée d'échantillons génomiques
WO2025174774A1 (fr) 2024-02-12 2025-08-21 Illumina, Inc. Détermination de corrections hors ligne pour des erreurs spécifiques de séquence provoquées par des séquences nucléotidiques de faible complexité
WO2025174708A1 (fr) 2024-02-13 2025-08-21 Illumina, Inc. Conception et procédé de compatibilité inter-plateformes de séquençage de cuves à circulation
WO2025178951A1 (fr) 2024-02-22 2025-08-28 Illumina, Inc. Techniques de regroupement par compression de la plage dynamique dans les dosages d'analytes
WO2025184234A1 (fr) 2024-02-28 2025-09-04 Illumina, Inc. Base de données d'haplotypes personnalisée pour mappage et alignement améliorés de lectures de nucléotides et appel de génotype amélioré
WO2025193747A1 (fr) 2024-03-12 2025-09-18 Illumina, Inc. Modèles d'apprentissage automatique pour ordonner et accélérer les tâches de séquençage ou les lames d'échantillons de nucléotides correspondantes
US12421558B2 (en) 2020-02-13 2025-09-23 10X Genomics, Inc. Systems and methods for joint interactive visualization of gene expression and DNA chromatin accessibility
US12421546B2 (en) 2007-01-26 2025-09-23 Illumina, Inc. Nucleic acid sequencing system
WO2025207535A1 (fr) 2024-03-26 2025-10-02 Illumina, Inc. Surfaces photocommutables
US12443849B2 (en) 2020-02-20 2025-10-14 Illumina, Inc. Bus network for artificial intelligence-based base caller
US12444482B2 (en) 2021-04-15 2025-10-14 Illumina, Inc. Multi-channel protein voxelization to predict variant pathogenicity using deep convolutional neural networks
WO2025217057A1 (fr) 2024-04-08 2025-10-16 Illumina, Inc. Détection de variante à l'aide d'alignements de données de séquence améliorés
WO2025240924A1 (fr) 2024-05-17 2025-11-20 Illumina, Inc. Systèmes d'égalisation aveugle pour applications d'appel de base
WO2025240241A1 (fr) 2024-05-13 2025-11-20 Illumina, Inc. Modification de cycles de séquençage pendant une analyse de séquençage pour satisfaire des estimations de couverture personnalisées pour une région génomique cible

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49362E1 (en) 2006-05-18 2023-01-10 Illumina Cambridge Limited Dye compounds and the use of their labelled conjugates

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045705A2 (fr) * 1997-04-09 1998-10-15 Biosite Diagnostics Incorporated Nouvelles compositions, et procedes d'inhibition de l'inactivation induite par la lumiere de reactifs biologiques
WO2000018957A1 (fr) * 1998-09-30 2000-04-06 Applied Research Systems Ars Holding N.V. Procedes d'amplification et de sequençage d'acide nucleique
WO2000070073A1 (fr) * 1999-05-19 2000-11-23 Cornell Research Foundation, Inc. Procede de mise en sequences de molecules d'acide nucleique
WO2001094630A2 (fr) * 2000-06-07 2001-12-13 Baylor College Of Medicine Compositions et methodes d'hybridation d'acides nucleiques a partir de jeux d'echantillons
WO2002086145A2 (fr) * 2001-04-24 2002-10-31 3M Innovative Properties Company Procedes de traitement d'echantillons biologiques et compositions comprenant des agents de surface
US20040241742A1 (en) * 2003-05-30 2004-12-02 Peck Bill J. Ligand array processing methods that include a low surface tension fluid deposition step and compositions for practicing the same
WO2004108966A1 (fr) * 2003-05-30 2004-12-16 Agilent Technologies Inc. Dosages en jeux de ligands a faible degradation des colorants fluorescents et compositions pour leur mise en pratique
WO2005040425A2 (fr) * 2003-10-20 2005-05-06 Isis Innovation Ltd Methodes de sequençage de polymeres en parallele

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE309390T1 (de) † 1998-07-30 2005-11-15 Solexa Ltd Matrizen von biomolekülen und ihre verwendung in sequenzierung
US7057026B2 (en) * 2001-12-04 2006-06-06 Solexa Limited Labelled nucleotides
ES2326077T3 (es) * 2002-08-23 2009-09-30 Illumina Cambridge Limited Nucleotidos marcados.

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045705A2 (fr) * 1997-04-09 1998-10-15 Biosite Diagnostics Incorporated Nouvelles compositions, et procedes d'inhibition de l'inactivation induite par la lumiere de reactifs biologiques
WO2000018957A1 (fr) * 1998-09-30 2000-04-06 Applied Research Systems Ars Holding N.V. Procedes d'amplification et de sequençage d'acide nucleique
WO2000070073A1 (fr) * 1999-05-19 2000-11-23 Cornell Research Foundation, Inc. Procede de mise en sequences de molecules d'acide nucleique
WO2001094630A2 (fr) * 2000-06-07 2001-12-13 Baylor College Of Medicine Compositions et methodes d'hybridation d'acides nucleiques a partir de jeux d'echantillons
WO2002086145A2 (fr) * 2001-04-24 2002-10-31 3M Innovative Properties Company Procedes de traitement d'echantillons biologiques et compositions comprenant des agents de surface
US20040241742A1 (en) * 2003-05-30 2004-12-02 Peck Bill J. Ligand array processing methods that include a low surface tension fluid deposition step and compositions for practicing the same
WO2004108966A1 (fr) * 2003-05-30 2004-12-16 Agilent Technologies Inc. Dosages en jeux de ligands a faible degradation des colorants fluorescents et compositions pour leur mise en pratique
WO2005040425A2 (fr) * 2003-10-20 2005-05-06 Isis Innovation Ltd Methodes de sequençage de polymeres en parallele

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MITRA R D ET AL: "Fluorescent in situ sequencing on polymerase colonies", ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 320, no. 1, 1 September 2003 (2003-09-01), pages 55 - 65, XP004441395, ISSN: 0003-2697 *

Cited By (505)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10525437B2 (en) 2004-01-07 2020-01-07 Illumina Cambridge Limited Methods and compositions of localizing nucleic acids to arrays
US10953379B2 (en) 2004-01-07 2021-03-23 Illumina Cambridge Limited Methods and compositions of localizing nucleic acids to arrays
US9376710B2 (en) 2004-01-07 2016-06-28 Illumina Cambridge Ltd. Methods of localizing nucleic acids to arrays
US9889422B2 (en) 2004-01-07 2018-02-13 Illumina Cambridge Limited Methods of localizing nucleic acids to arrays
US11654411B2 (en) 2004-01-07 2023-05-23 Illumina Cambridge Limited Methods and compositions of localizing nucleic acids to arrays
US9498763B2 (en) 2005-07-20 2016-11-22 Illumina Cambridge Limited Preparation of templates for nucleic acid sequencing
US10710046B2 (en) 2005-07-20 2020-07-14 Illumina Cambridge Limited Preparation of templates for nucleic acid sequencing
US8715966B2 (en) * 2005-07-20 2014-05-06 Illumina Cambridge Limited Preparation of templates for nucleic acid sequencing
US9999866B2 (en) 2005-07-20 2018-06-19 Illumina Cambridge Limited Preparation of templates for nucleic acid sequencing
US9085802B2 (en) 2005-07-20 2015-07-21 Illumina Cambridge Limited Preparation of templates for nucleic acid sequencing
US20120208194A1 (en) * 2005-07-20 2012-08-16 Illumina Cambridge Limited Preparation of Templates for Nucleic Acid Sequencing
EP2918686A1 (fr) 2005-11-25 2015-09-16 Illumina Cambridge Limited Preparation de matrices d'acides nucleiques pour leur amplification en phase solide
EP4105644A2 (fr) 2006-03-31 2022-12-21 Illumina, Inc. Systèmes et procédés pour analyse de séquençage par synthèse
EP3722409A1 (fr) 2006-03-31 2020-10-14 Illumina, Inc. Systèmes et procédés pour analyse de séquençage par synthèse
EP3373174A1 (fr) 2006-03-31 2018-09-12 Illumina, Inc. Systèmes et procédés pour analyse de séquençage par synthèse
US9415368B2 (en) 2006-06-23 2016-08-16 Illumina, Inc. Devices and systems for creation of DNA cluster arrays
US8921073B2 (en) 2006-06-23 2014-12-30 Illumina, Inc. Devices and systems for creation of DNA cluster arrays
EP3670672A1 (fr) 2006-10-06 2020-06-24 Illumina Cambridge Limited Procédé de séquençage d'un modèle de polynucléotide
US8568979B2 (en) 2006-10-10 2013-10-29 Illumina, Inc. Compositions and methods for representational selection of nucleic acids from complex mixtures using hybridization
US9587273B2 (en) 2006-10-10 2017-03-07 Illumina, Inc. Compositions and methods for representational selection of nucleic acids from complex mixtures using hybridization
US9340781B2 (en) 2006-10-10 2016-05-17 Illumina, Inc. Compositions and methods for representational selection of nucleic acids from complex mixtures using hybridization
US9139826B2 (en) 2006-10-10 2015-09-22 Illumina, Inc. Compositions and methods for representational selection of nucleic acids from complex mixtures using hybridization
US10538759B2 (en) 2006-10-10 2020-01-21 Illumina, Inc. Compounds and method for representational selection of nucleic acids from complex mixtures using hybridization
US8916350B2 (en) 2006-10-10 2014-12-23 Illumina, Inc. Compositions and methods for representational selection of nucleic acids from complex mixtures using hybridization
US8914241B2 (en) 2007-01-26 2014-12-16 Illumina, Inc. Nucleic acid sequencing system and method
US8725425B2 (en) 2007-01-26 2014-05-13 Illumina, Inc. Image data efficient genetic sequencing method and system
US9797012B2 (en) 2007-01-26 2017-10-24 Illumina, Inc. Nucleic acid sequencing system and method
US8244479B2 (en) 2007-01-26 2012-08-14 Illumina, Inc. Nucleic acid sequencing system and method using a subset of sites of a substrate
US8315817B2 (en) 2007-01-26 2012-11-20 Illumina, Inc. Independently removable nucleic acid sequencing system and method
US10053730B2 (en) 2007-01-26 2018-08-21 Illumina, Inc. Independently removable nucleic acid sequencing system and method
US8412467B2 (en) 2007-01-26 2013-04-02 Illumina, Inc. Nucleic acid sequencing system and method
US9121063B2 (en) 2007-01-26 2015-09-01 Illumina, Inc. Independently removable nucleic acid sequencing system and method
US7835871B2 (en) * 2007-01-26 2010-11-16 Illumina, Inc. Nucleic acid sequencing system and method
US12435371B2 (en) 2007-01-26 2025-10-07 Illumina, Inc. Nucleic acid sequencing system
US12421546B2 (en) 2007-01-26 2025-09-23 Illumina, Inc. Nucleic acid sequencing system
US11499191B2 (en) 2007-01-26 2022-11-15 Illumina, Inc. Independently removable nucleic acid sequencing system and method
US11940413B2 (en) 2007-02-05 2024-03-26 IsoPlexis Corporation Methods and devices for sequencing nucleic acids in smaller batches
US12227803B2 (en) 2008-01-28 2025-02-18 Complete Genomics, Inc. Methods and compositions for efficient base calling in sequencing reactions
US11098356B2 (en) 2008-01-28 2021-08-24 Complete Genomics, Inc. Methods and compositions for nucleic acid sequencing
US11214832B2 (en) 2008-01-28 2022-01-04 Complete Genomics, Inc. Methods and compositions for efficient base calling in sequencing reactions
US12227798B2 (en) 2008-03-19 2025-02-18 IsoPlexis Corporation Methods and compositions for incorporating nucleotides
US8698102B2 (en) 2008-05-05 2014-04-15 Illumina, Inc. Compensator for multiple surface imaging
USRE49884E1 (en) 2008-05-05 2024-03-26 Illumina, Inc. Compensator for multiple surface imaging
US8143599B2 (en) 2008-05-05 2012-03-27 Illumina, Inc. Compensator for multiple surface imaging
US8278630B1 (en) 2008-05-05 2012-10-02 Illumina, Inc. Compensator for multiple surface imaging
US8039817B2 (en) 2008-05-05 2011-10-18 Illumina, Inc. Compensator for multiple surface imaging
US8071962B1 (en) 2008-05-05 2011-12-06 Illumina, Inc. Compensator for multiple surface imaging
US9365898B2 (en) 2008-05-05 2016-06-14 Illumina, Inc. Compensator for multiple surface imaging
USRE48561E1 (en) 2008-05-05 2021-05-18 Illumina, Inc. Compensator for multiple surface imaging
USRE48219E1 (en) 2008-05-05 2020-09-22 Illumina, Inc. Compensator for multiple surface imaging
US9068220B2 (en) 2008-05-05 2015-06-30 Illumina, Inc. Compensator for multiple surface imaging
US8546772B2 (en) 2008-05-05 2013-10-01 Illumina, Inc. Compensator for multiple surface imaging
US8586947B1 (en) 2008-05-05 2013-11-19 Illumina, Inc. Compensator for multiple surface imaging
US8242463B2 (en) 2008-05-05 2012-08-14 Illumina, Inc. Compensator for multiple surface imaging
US11866780B2 (en) * 2008-10-02 2024-01-09 Illumina Cambridge Limited Nucleic acid sample enrichment for sequencing applications
WO2010062775A2 (fr) 2008-11-03 2010-06-03 The Regents Of The University Of California Procédés de détection d'acides nucléiques résistant à une modification
US9677068B2 (en) 2008-11-03 2017-06-13 The Regents Of The University Of California Methods for detecting modification resistant nucleic acids
US8486865B2 (en) 2008-11-03 2013-07-16 The Regents Of The University Of California Methods for detecting modification resistant nucleic acids
US9284547B2 (en) 2008-11-03 2016-03-15 The Regents Of The University Of California Methods for detecting modification resistant nucleic acids
US8236532B2 (en) 2008-12-23 2012-08-07 Illumina, Inc. Multibase delivery for long reads in sequencing by synthesis protocols
US8709729B2 (en) 2008-12-23 2014-04-29 Illumina, Inc. Method of making an array of nucleic acid colonies
US8476022B2 (en) 2008-12-23 2013-07-02 Illumina, Inc. Method of making an array of nucleic acid colonies
US9416415B2 (en) 2008-12-23 2016-08-16 Illumina, Inc. Method of sequencing nucleic acid colonies formed on a surface by re-seeding
US9005929B2 (en) 2008-12-23 2015-04-14 Illumina, Inc. Multibase delivery for long reads in sequencing by synthesis protocols
US10167506B2 (en) 2008-12-23 2019-01-01 Illumina, Inc. Method of sequencing nucleic acid colonies formed on a patterned surface by re-seeding
EP2607496A1 (fr) 2008-12-23 2013-06-26 Illumina, Inc. Procédés utiles dans des protocoles de séquençage d'acide nucléique
US11156603B2 (en) 2010-04-05 2021-10-26 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11542543B2 (en) 2010-04-05 2023-01-03 Prognosys Biosciences, Inc. System for analyzing targets of a tissue section
US11733238B2 (en) 2010-04-05 2023-08-22 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11293917B2 (en) 2010-04-05 2022-04-05 Prognosys Biosciences, Inc. Systems for analyzing target biological molecules via sample imaging and delivery of probes to substrate wells
US11732292B2 (en) 2010-04-05 2023-08-22 Prognosys Biosciences, Inc. Spatially encoded biological assays correlating target nucleic acid to tissue section location
US12391979B2 (en) 2010-04-05 2025-08-19 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11634756B2 (en) 2010-04-05 2023-04-25 Prognosys Biosciences, Inc. Spatially encoded biological assays
US12297488B2 (en) 2010-04-05 2025-05-13 Prognosys Biosciences, Inc. Spatially encoded biological assays
US12391980B2 (en) 2010-04-05 2025-08-19 Prognosys Biosciences, Inc. Spatially encoded biological assays
US12297487B2 (en) 2010-04-05 2025-05-13 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11313856B2 (en) 2010-04-05 2022-04-26 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11479810B1 (en) 2010-04-05 2022-10-25 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11866770B2 (en) 2010-04-05 2024-01-09 Prognosys Biosciences, Inc. Spatially encoded biological assays
US12234505B2 (en) 2010-04-05 2025-02-25 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11365442B2 (en) 2010-04-05 2022-06-21 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11371086B2 (en) 2010-04-05 2022-06-28 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11761030B2 (en) 2010-04-05 2023-09-19 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11208684B2 (en) 2010-04-05 2021-12-28 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11767550B2 (en) 2010-04-05 2023-09-26 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11384386B2 (en) 2010-04-05 2022-07-12 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11401545B2 (en) 2010-04-05 2022-08-02 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11519022B2 (en) 2010-04-05 2022-12-06 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11549138B2 (en) 2010-04-05 2023-01-10 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11560587B2 (en) 2010-04-05 2023-01-24 Prognosys Biosciences, Inc. Spatially encoded biological assays
WO2012025250A1 (fr) 2010-08-27 2012-03-01 Illumina Cambridge Ltd. Méthodes de séquençage de polynucléotides
US9029103B2 (en) 2010-08-27 2015-05-12 Illumina Cambridge Limited Methods for sequencing polynucleotides
US10329613B2 (en) 2010-08-27 2019-06-25 Illumina Cambridge Limited Methods for sequencing polynucleotides
US11279975B2 (en) 2010-08-27 2022-03-22 Illumina Cambridge Limited Methods for sequencing polynucleotides
US12319962B2 (en) 2010-08-27 2025-06-03 Illumina Cambridge Limited Methods for sequencing polynucleotides
EP2801623A1 (fr) 2010-08-27 2014-11-12 Illumina Cambridge Limited Méthodes de séquencage de polynucléotides
EP3205730A1 (fr) 2010-08-27 2017-08-16 Illumina Cambridge Limited Méthodes de séquencage en «paired end» de polynucléotides
US8483969B2 (en) 2010-09-17 2013-07-09 Illuminia, Inc. Variation analysis for multiple templates on a solid support
US9222134B2 (en) 2010-09-17 2015-12-29 Illumina, Inc. Molecule detection system on a solid support
WO2012050920A1 (fr) 2010-09-29 2012-04-19 Illumina, Inc. Compositions et procédés de séquençage d'acides nucléiques
WO2012055929A1 (fr) 2010-10-26 2012-05-03 Illumina, Inc. Procédés de séquençage
EP3928867A1 (fr) 2010-10-27 2021-12-29 Illumina, Inc. Microdispositifs et cartouches de biocapteur pour analyse chimique ou biologique et systèmes et procédés correspondants
WO2012058096A1 (fr) 2010-10-27 2012-05-03 Illumina, Inc. Microdispositifs et cartouches de biocapteurs pour analyse biologique ou chimique et systèmes et procédés associés
US8575071B2 (en) 2010-11-03 2013-11-05 Illumina, Inc. Reducing adapter dimer formation
US9506055B2 (en) 2010-11-03 2016-11-29 Illumina, Inc. Reducing adapter dimer formation
WO2012061036A1 (fr) 2010-11-03 2012-05-10 Illumina, Inc. Réduction de la formation de dimères adaptères
US10233443B2 (en) 2010-11-03 2019-03-19 Illumina, Inc. Reducing adapter dimer formation
WO2012061832A1 (fr) 2010-11-05 2012-05-10 Illumina, Inc. Liaison entre des lectures de séquences à l'aide de codes marqueurs appariés
US9284604B2 (en) 2010-11-22 2016-03-15 The Regents Of The University Of California Methods of identifying a cellular nascent RNA transcript
US12151241B2 (en) 2011-01-10 2024-11-26 Illumina, Inc. Systems, methods, and apparatuses to image a sample for biological or chemical analysis
US9115353B2 (en) 2011-01-31 2015-08-25 Illumina, Inc. Method for nucleotide detection
WO2012106081A2 (fr) 2011-01-31 2012-08-09 Illumina, Inc. Procédés pour réduire les dommages occasionnés aux acides nucléiques
EP2670864A2 (fr) * 2011-01-31 2013-12-11 Illumina, Inc. Procédés pour réduire les dommages occasionnés aux acides nucléiques
US9856529B2 (en) 2011-01-31 2018-01-02 Illumina, Inc. Method for nucleotide detection
EP2670864A4 (fr) * 2011-01-31 2014-09-17 Illumina Inc Procédés pour réduire les dommages occasionnés aux acides nucléiques
US10106851B2 (en) 2011-01-31 2018-10-23 Illumina, Inc. Method for nucleotide detection
US11479809B2 (en) 2011-04-13 2022-10-25 Spatial Transcriptomics Ab Methods of detecting analytes
US11795498B2 (en) 2011-04-13 2023-10-24 10X Genomics Sweden Ab Methods of detecting analytes
US11352659B2 (en) 2011-04-13 2022-06-07 Spatial Transcriptomics Ab Methods of detecting analytes
US11788122B2 (en) 2011-04-13 2023-10-17 10X Genomics Sweden Ab Methods of detecting analytes
WO2013049135A1 (fr) 2011-09-26 2013-04-04 Gen-Probe Incorporated Algorithmes de détermination de séquences
WO2013070627A2 (fr) 2011-11-07 2013-05-16 Illumina, Inc. Appareils de séquençage intégré et procédés d'utilisation
US8637242B2 (en) 2011-11-07 2014-01-28 Illumina, Inc. Integrated sequencing apparatuses and methods of use
US9309571B2 (en) 2011-11-07 2016-04-12 Illumina, Inc. Integrated sequencing apparatuses and methods of use
US10167505B2 (en) 2011-11-07 2019-01-01 Illumina, Inc. Integrated sequencing apparatuses and methods of use
WO2013085710A2 (fr) 2011-12-09 2013-06-13 Illumina, Inc. Base de numération étendue pour étiquettes polymères
WO2013117595A2 (fr) 2012-02-07 2013-08-15 Illumina Cambridge Limited Enrichissement et amplification ciblés d'acides nucléiques sur un support
EP3037552A1 (fr) 2012-03-06 2016-06-29 Illumina Cambridge Limited Procédés améliorés de séquençage d'acide nucléique
WO2013131962A1 (fr) 2012-03-06 2013-09-12 Illumina Cambridge Limited Procédés améliorés de séquençage d'acides nucléiques
US11031132B2 (en) 2012-04-11 2021-06-08 Illumina, Inc. Cloud computing environment for biological data
US10223502B2 (en) 2012-04-11 2019-03-05 Illumina, Inc. Cloud computing environment for biological data
US11894135B2 (en) 2012-04-11 2024-02-06 Illumina, Inc. Cloud computing environment for biological data
US9444880B2 (en) 2012-04-11 2016-09-13 Illumina, Inc. Cloud computing environment for biological data
WO2014008448A1 (fr) 2012-07-03 2014-01-09 Sloan Kettering Institute For Cancer Research Évaluation quantitative de la reconstitution du répertoire des cellules t chez l'homme après une greffe allogénique de cellules souches hématopoïétiques
USRE50065E1 (en) 2012-10-17 2024-07-30 10X Genomics Sweden Ab Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
US9989544B2 (en) 2012-11-05 2018-06-05 Illumina, Inc. Sequence scheduling and sample distribution techniques
US9116139B2 (en) 2012-11-05 2015-08-25 Illumina, Inc. Sequence scheduling and sample distribution techniques
EP3486331A1 (fr) 2013-01-09 2019-05-22 Illumina Cambridge Limited Préparation d'échantillons sur un support solide
WO2014108810A2 (fr) 2013-01-09 2014-07-17 Lumina Cambridge Limited Préparation d'échantillon sur un support solide
EP4417692A2 (fr) 2013-01-09 2024-08-21 Illumina Cambridge Limited Préparation d'échantillons sur un support solide
US9805407B2 (en) 2013-01-25 2017-10-31 Illumina, Inc. Methods and systems for using a cloud computing environment to configure and sell a biological sample preparation cartridge and share related data
WO2014116851A2 (fr) 2013-01-25 2014-07-31 Illumina, Inc. Procédés et systèmes pour utiliser un environnement informatique en nuage pour partager des données biologiques
US10217156B2 (en) 2013-01-25 2019-02-26 Illumina, Inc. Methods and systems for using a cloud computing environment to share biological related data
EP3919617A1 (fr) 2013-03-13 2021-12-08 Illumina, Inc. Procédés et compositions de séquençage d'acide nucléique
WO2014142850A1 (fr) 2013-03-13 2014-09-18 Illumina, Inc. Procédés et compositions pour le séquençage d'acide nucléique
EP3553175A1 (fr) 2013-03-13 2019-10-16 Illumina, Inc. Procédés et compositions de séquençage d'acide nucléique
US11286515B2 (en) 2013-06-25 2022-03-29 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11753674B2 (en) 2013-06-25 2023-09-12 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11618918B2 (en) 2013-06-25 2023-04-04 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11821024B2 (en) 2013-06-25 2023-11-21 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11359228B2 (en) 2013-06-25 2022-06-14 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US12303888B2 (en) 2013-09-27 2025-05-20 Illumina, Inc. Method to produce chemical pattern in micro-fluidic structure
US10486153B2 (en) 2013-09-27 2019-11-26 Illumina, Inc. Method to produce chemical pattern in micro-fluidic structure
US11298697B2 (en) 2013-09-27 2022-04-12 Illumina, Inc. Method to produce chemical pattern in micro-fluidic structure
US11308640B2 (en) 2013-11-01 2022-04-19 Illumina, Inc. Image analysis useful for patterned objects
US10540783B2 (en) 2013-11-01 2020-01-21 Illumina, Inc. Image analysis useful for patterned objects
WO2015084985A2 (fr) 2013-12-03 2015-06-11 Illumina, Inc. Procédés et systèmes d'analyse de données d'image
EP3940082A1 (fr) 2013-12-03 2022-01-19 Illumina, Inc. Procédé et système permettant d'analyser des données d'image
EP3715467A1 (fr) 2013-12-03 2020-09-30 Illumina, Inc. Procédé et système permettant d'analyser des données d'image
US12140543B2 (en) 2013-12-10 2024-11-12 Illumina, Inc. Biosensors for biological or chemical analysis and methods of manufacturing the same
EP4220137A1 (fr) 2013-12-10 2023-08-02 Illumina, Inc. Biocapteurs pour analyse biologique ou chimique et leurs procédés de fabrication
US11719637B2 (en) 2013-12-10 2023-08-08 Illumina, Inc. Biosensors for biological or chemical analysis and methods of manufacturing the same
US11181478B2 (en) 2013-12-10 2021-11-23 Illumina, Inc. Biosensors for biological or chemical analysis and methods of manufacturing the same
US10537889B2 (en) 2013-12-31 2020-01-21 Illumina, Inc. Addressable flow cell using patterned electrodes
WO2015103225A1 (fr) 2013-12-31 2015-07-09 Illumina, Inc. Cuve à circulation adressable utilisant des électrodes à motif
WO2015123444A2 (fr) 2014-02-13 2015-08-20 Illumina, Inc. Services génomiques au consommateur intégrés
EP3910069A1 (fr) 2014-02-18 2021-11-17 Illumina, Inc. Procédés et composition de profilage d'adn
US11174513B2 (en) 2014-03-11 2021-11-16 Illumina, Inc. Disposable, integrated microfluidic cartridge and methods of making and using same
EP3698874A1 (fr) 2014-03-11 2020-08-26 Illumina, Inc. Cartouche microfluidique intégrée et jetable et leurs procédés de fabrication
US10767219B2 (en) 2014-03-11 2020-09-08 Illumina, Inc. Disposable, integrated microfluidic cartridge and methods of making and using same
WO2015175832A1 (fr) 2014-05-16 2015-11-19 Illumina, Inc. Techniques de synthèse d'acide nucléique
US10570447B2 (en) 2014-05-16 2020-02-25 Illumina, Inc. Nucleic acid synthesis techniques
US12416048B2 (en) 2014-05-16 2025-09-16 Illumina, Inc. Nucleic acid synthesis techniques
US12179190B2 (en) 2014-05-27 2024-12-31 Illumina, Inc. Systems and methods for biochemical analysis including a base instrument and a removable cartridge
US11590494B2 (en) 2014-05-27 2023-02-28 Illumina, Inc. Systems and methods for biochemical analysis including a base instrument and a removable cartridge
WO2015183871A1 (fr) 2014-05-27 2015-12-03 Illumina, Inc. Systèmes et procédés d'analyse biochimique comprenant un instrument de base et une cartouche amovible
EP3699289A1 (fr) 2014-06-09 2020-08-26 Illumina Cambridge Limited Préparation d'échantillons pour l'amplification d'acide nucléique
EP4039815A1 (fr) 2014-06-09 2022-08-10 Illumina Cambridge Limited Préparation d'échantillons pour l'amplification d'acide nucléique
WO2016040602A1 (fr) 2014-09-11 2016-03-17 Epicentre Technologies Corporation Séquence au bisulfite à représentation réduite utilisant de l'uracile n-glycosylase (ung) et de l'endonucléase iv
WO2016061484A2 (fr) 2014-10-16 2016-04-21 Illumina, Inc. Systèmes de balayage optique pour analyse génétique in situ
EP3974538A1 (fr) 2014-11-05 2022-03-30 Illumina Cambridge Limited Séquençage à partir de multiples amorces pour accroître le débit et la densité des données
US11555218B2 (en) 2014-11-05 2023-01-17 Illumina Cambridge Limited Sequencing from multiple primers to increase data rate and density
WO2016073237A1 (fr) 2014-11-05 2016-05-12 Illumina Cambridge Limited Réduction des dommages sur l'adn pendant la préparation et le séquençage d'échantillons au moyen de chélateurs de sidérophores
US12385092B2 (en) 2014-11-11 2025-08-12 Illumina Cambridge Limited Methods and arrays for producing and sequencing monoclonal clusters of nucleic acid
US11692223B2 (en) 2014-11-11 2023-07-04 Illumina Cambridge Limited Methods and arrays for producing and sequencing monoclonal clusters of nucleic acid
US10619204B2 (en) 2014-11-11 2020-04-14 Illumina Cambridge Limited Methods and arrays for producing and sequencing monoclonal clusters of nucleic acid
EP3725893A1 (fr) 2015-02-10 2020-10-21 Illumina, Inc. Compositions pour l'analyse de composants cellulaires
US10576471B2 (en) 2015-03-20 2020-03-03 Illumina, Inc. Fluidics cartridge for use in the vertical or substantially vertical position
EP3783109A1 (fr) 2015-03-31 2021-02-24 Illumina Cambridge Limited Surface de concamerisation de matrices
US12123056B2 (en) 2015-03-31 2024-10-22 Illumina Cambridge Limited Surface concatemerization of templates
US11162132B2 (en) 2015-04-10 2021-11-02 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11613773B2 (en) 2015-04-10 2023-03-28 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11299774B2 (en) 2015-04-10 2022-04-12 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11390912B2 (en) 2015-04-10 2022-07-19 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11739372B2 (en) 2015-04-10 2023-08-29 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US10844428B2 (en) 2015-04-28 2020-11-24 Illumina, Inc. Error suppression in sequenced DNA fragments using redundant reads with unique molecular indices (UMIS)
US11866777B2 (en) 2015-04-28 2024-01-09 Illumina, Inc. Error suppression in sequenced DNA fragments using redundant reads with unique molecular indices (UMIS)
US10590464B2 (en) 2015-05-29 2020-03-17 Illumina Cambridge Limited Enhanced utilization of surface primers in clusters
WO2016196358A1 (fr) 2015-05-29 2016-12-08 Epicentre Technologies Corporation Méthodes d'analyse d'acides nucléiques
US12157910B2 (en) 2015-07-06 2024-12-03 Illumina Cambridge Limited Sample preparation for nucleic acid amplification
EP3878974A1 (fr) 2015-07-06 2021-09-15 Illumina Cambridge Limited Préparation d'échantillons pour l'amplification d'acide nucléique
WO2017019456A2 (fr) 2015-07-27 2017-02-02 Illumina, Inc. Cartographie spatiale d'informations de séquence d'acide nucléique
EP3957747A1 (fr) 2015-07-27 2022-02-23 Illumina, Inc. Cartographie spatiale d'informations de séquence d'acide nucléique
EP3854884A1 (fr) 2015-08-14 2021-07-28 Illumina, Inc. Systèmes et procédés mettant en oeuvre des capteurs à sensibilité magnétique pour la détermination d'une caractéristique génétique
US11512348B2 (en) 2015-08-14 2022-11-29 Illumina, Inc. Systems and methods using magnetically-responsive sensors for determining a genetic characteristic
US10976334B2 (en) 2015-08-24 2021-04-13 Illumina, Inc. In-line pressure accumulator and flow-control system for biological or chemical assays
US10450598B2 (en) 2015-09-11 2019-10-22 Illumina, Inc. Systems and methods for obtaining a droplet having a designated concentration of a substance-of-interest
EP3940083A1 (fr) 2015-10-07 2022-01-19 Illumina, Inc. Réduction de capture hors cible dans des techniques de séquençage
US10253352B2 (en) 2015-11-17 2019-04-09 Omniome, Inc. Methods for determining sequence profiles
WO2018018008A1 (fr) 2016-07-22 2018-01-25 Oregon Health & Science University Bibliothèques de génome entier de cellules uniques et procédés d'indexage combinatoire pour leur fabrication
US11535883B2 (en) 2016-07-22 2022-12-27 Illumina, Inc. Single cell whole genome libraries and combinatorial indexing methods of making thereof
EP3904514A1 (fr) 2016-07-22 2021-11-03 Oregon Health & Science University Bibliothèques de génome entier de cellules uniques et procédés d'indexage combinatoire pour leur fabrication
WO2018057770A1 (fr) 2016-09-22 2018-03-29 Illumina, Inc. Détection de la variation du nombre de copies somatiques
EP4439045A2 (fr) 2016-10-14 2024-10-02 Illumina, Inc. Ensemble cartouche
EP3308860A1 (fr) 2016-10-14 2018-04-18 Illumina, Inc. Ensemble de cartouche
US10343160B2 (en) 2016-10-14 2019-07-09 Illumina, Inc. Cartridge assembly
US11458469B2 (en) 2016-10-14 2022-10-04 Illumina, Inc. Cartridge assembly
US11150179B2 (en) 2017-01-06 2021-10-19 Illumina, Inc. Phasing correction
US12455229B2 (en) 2017-01-06 2025-10-28 Illumina, Inc. Phasing correction
WO2018129314A1 (fr) 2017-01-06 2018-07-12 Illumina, Inc. Correction de phase
WO2018136416A1 (fr) 2017-01-17 2018-07-26 Illumina, Inc. Détermination de variant d'épissage oncogène
US11761035B2 (en) 2017-01-18 2023-09-19 Illumina, Inc. Methods and systems for generation and error-correction of unique molecular index sets with heterogeneous molecular lengths
US10844429B2 (en) 2017-01-18 2020-11-24 Illumina, Inc. Methods and systems for generation and error-correction of unique molecular index sets with heterogeneous molecular lengths
WO2018136117A1 (fr) 2017-01-20 2018-07-26 Omniome, Inc. Capture spécifique d'un allèle d'acides nucléiques
WO2018136118A1 (fr) 2017-01-20 2018-07-26 Omniome, Inc. Génotypage par liaison par polymérase
WO2018175798A1 (fr) 2017-03-24 2018-09-27 Life Technologies Corporation Adaptateurs polynucléotidiques et procédés d'utilisation de ces derniers
EP4053294A1 (fr) 2017-03-24 2022-09-07 Life Technologies Corporation Adaptateurs polynucléotidiques et procédés d'utilisation de ces derniers
WO2018200380A1 (fr) 2017-04-23 2018-11-01 Illumina, Inc. Compositions et procédés d'amélioration de l'identification d'échantillons dans des bibliothèques indexées d'acides nucléiques
EP3842545A1 (fr) 2017-04-23 2021-06-30 Illumina, Inc. Compositions et procédés pour améliorer l'identification d'échantillons dans des bibliothèques d'acides nucléiques indexés
EP3872187A1 (fr) 2017-04-23 2021-09-01 Illumina Cambridge Limited Compositions et procédés d'amélioration de l'identification d'échantillons dans des bibliothèques indexées d'acides nucléiques
EP3913053A1 (fr) 2017-04-23 2021-11-24 Illumina Cambridge Limited Compositions et procédés permettant d'améliorer l'identification d'échantillons dans des bibliothèques d'acides nucléiques indexés
WO2018197945A1 (fr) 2017-04-23 2018-11-01 Illumina Cambridge Limited Compositions et procédés permettant d'améliorer l'identification d'échantillons dans des bibliothèques d'acides nucléiques indexés
WO2018200386A1 (fr) 2017-04-23 2018-11-01 Illumina, Inc. Compositions et procédés pour améliorer l'identification d'échantillons dans des bibliothèques d'acides nucléiques indexés
WO2018197950A1 (fr) 2017-04-23 2018-11-01 Illumina Cambridge Limited Compositions et procédés pour améliorer l'identification d'échantillons dans des bibliothèques d'acides nucléiques indexées
WO2018204423A1 (fr) 2017-05-01 2018-11-08 Illumina, Inc. Séquences index optimales pour séquençage multiplex massivement parallèle
US11788139B2 (en) 2017-05-01 2023-10-17 Illumina, Inc. Optimal index sequences for multiplex massively parallel sequencing
US11028435B2 (en) 2017-05-01 2021-06-08 Illumina, Inc. Optimal index sequences for multiplex massively parallel sequencing
US11028436B2 (en) 2017-05-08 2021-06-08 Illumina, Inc. Universal short adapters for indexing of polynucleotide samples
EP4443436A2 (fr) 2017-05-08 2024-10-09 Illumina, Inc. Adaptateurs courts universels pour l'indexation de polynucléotides
WO2018208699A1 (fr) 2017-05-08 2018-11-15 Illumina, Inc. Courts adaptateurs universels pour l'indexage d'échantillons de polynucléotides
US11814678B2 (en) 2017-05-08 2023-11-14 Illumina, Inc. Universal short adapters for indexing of polynucleotide samples
WO2018213803A1 (fr) 2017-05-19 2018-11-22 Neon Therapeutics, Inc. Identification de néo-antigène immunogène
EP4293122A2 (fr) 2017-06-07 2023-12-20 Oregon Health & Science University Banques de génomes entiers de cellules individuelles pour le séquençage de méthylation
EP3981884A1 (fr) 2017-06-07 2022-04-13 Oregon Health & Science University Banques de génomes entiers de cellules individuelles pour le séquençage de méthylation
WO2018226708A1 (fr) 2017-06-07 2018-12-13 Oregon Health & Science University Banques de génomes entiers de cellules individuelles pour le séquençage de méthylation
WO2018236631A1 (fr) 2017-06-20 2018-12-27 Illumina, Inc. Procédés et compositions pour résoudre les inefficacités dans des réactions d'amplification
WO2019027767A1 (fr) 2017-07-31 2019-02-07 Illumina Inc. Système de séquençage comportant une agrégation d'échantillons biologiques multiplexés
US11649498B2 (en) 2017-08-01 2023-05-16 Illumina, Inc. Spatial indexing of genetic material and library preparation using hydrogel beads and flow cells
EP4289967A2 (fr) 2017-08-01 2023-12-13 Illumina, Inc. Indexation spatiale de matériel génétique et préparation de pharmacothèque à l'aide de billes d'hydrogel et de cellules d'écoulement
US12428680B2 (en) 2017-08-01 2025-09-30 Illumina, Inc. Spatial indexing of genetic material and library preparation using hydrogel beads and flow cells
US11352668B2 (en) 2017-08-01 2022-06-07 Illumina, Inc. Spatial indexing of genetic material and library preparation using hydrogel beads and flow cells
WO2019028047A1 (fr) 2017-08-01 2019-02-07 Illumina, Inc Indexation spatiale de matériel génétique et préparation de pharmacothèque à l'aide de billes d'hydrogel et de cellules d'écoulement
US11326202B2 (en) 2017-08-01 2022-05-10 Helitec Limited Methods of enriching and determining target nucleotide sequences
WO2019023924A1 (fr) 2017-08-01 2019-02-07 Helitec Limited Procédés d'enrichissement et de détermination de séquences nucléotidiques cibles
EP4446437A2 (fr) 2017-08-01 2024-10-16 Illumina, Inc. Indexation spatiale de matériel génétique et préparation de bibliothèque à l'aide de billes d'hydrogel et de cellules d'écoulement
US11898198B2 (en) 2017-09-15 2024-02-13 Illumina, Inc. Universal short adapters with variable length non-random unique molecular identifiers
US11447818B2 (en) 2017-09-15 2022-09-20 Illumina, Inc. Universal short adapters with variable length non-random unique molecular identifiers
WO2019055715A1 (fr) 2017-09-15 2019-03-21 Illumina, Inc. Adaptateurs courts universels à identifiants moléculaires uniques non aléatoires de longueur variable
EP4289996A2 (fr) 2017-11-06 2023-12-13 Illumina Inc. Techniques d'indexation d'acide nucléique
WO2019090251A2 (fr) 2017-11-06 2019-05-09 Illumina, Inc. Techniques d'indexation d'acide nucléique
US12154664B2 (en) 2017-11-16 2024-11-26 Illumina, Inc. Systems and methods for determining microsatellite instability
WO2019099529A1 (fr) 2017-11-16 2019-05-23 Illumina, Inc. Systèmes et procédés de détermination d'une instabilité de microsatellite
US12040047B2 (en) 2017-11-30 2024-07-16 Illumina, Inc. Validation methods and systems for sequence variant calls
EP4579669A2 (fr) 2017-11-30 2025-07-02 Illumina, Inc. Procédés et systèmes de validation pour appels de variantes de séquence
WO2019108972A1 (fr) 2017-11-30 2019-06-06 Illumina, Inc. Procédés et systèmes de validation pour appels de variantes de séquences
WO2019136388A1 (fr) 2018-01-08 2019-07-11 Illumina, Inc. Systèmes et dispositifs de séquençage à haut débit avec détection basée sur un semi-conducteur
EP3913358A1 (fr) 2018-01-08 2021-11-24 Illumina Inc Séquençage à haut débit à détection à semi-conducteur
WO2019136376A1 (fr) 2018-01-08 2019-07-11 Illumina, Inc. Séquençage à haut débit à détection à semi-conducteur
US11953464B2 (en) 2018-01-08 2024-04-09 Illumina, Inc. Semiconductor-based biosensors for base calling
US11561196B2 (en) 2018-01-08 2023-01-24 Illumina, Inc. Systems and devices for high-throughput sequencing with semiconductor-based detection
WO2019195225A1 (fr) 2018-04-02 2019-10-10 Illumina, Inc. Compositions et procédés de préparation de témoins pour un test génétique basé sur une séquence
WO2019222688A1 (fr) 2018-05-17 2019-11-21 Illumina, Inc. Séquençage de cellules uniques à haut débit avec biais d'amplification réduit
US11981891B2 (en) 2018-05-17 2024-05-14 Illumina, Inc. High-throughput single-cell sequencing with reduced amplification bias
EP4269618A2 (fr) 2018-06-04 2023-11-01 Illumina, Inc. Procédés de production des bibliothèques de transcriptomes à une seule cellule à haut débit et leurs
US12083514B2 (en) 2018-07-03 2024-09-10 Illumina, Inc. Interposer with first and second adhesive layers
US12435362B2 (en) 2018-08-15 2025-10-07 Illumina, Inc. Compositions and methods for improving library enrichment
WO2020036991A1 (fr) 2018-08-15 2020-02-20 Illumina, Inc. Compositions et procédés pour améliorer l'enrichissement de bibliothèques
WO2020047007A2 (fr) 2018-08-28 2020-03-05 10X Genomics, Inc. Procédés de génération de matrices à codes-barres spatiaux
US11519033B2 (en) 2018-08-28 2022-12-06 10X Genomics, Inc. Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample
EP4464793A2 (fr) 2018-08-28 2024-11-20 10X Genomics, Inc. Procédés de génération de réseaux à code-barres spatiaux
US12378607B2 (en) 2018-08-28 2025-08-05 10X Genomics, Inc. Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample
EP4603594A2 (fr) 2018-08-28 2025-08-20 10x Genomics, Inc. Augmentation de la résolution d'un réseau spatial
WO2020047002A1 (fr) 2018-08-28 2020-03-05 10X Genomics, Inc. Procédé de marquage spatial induit par transposase et d'analyse d'adn génomique dans un échantillon biologique
WO2020047005A1 (fr) 2018-08-28 2020-03-05 10X Genomics, Inc. Résolution de réseaux spatiaux
US12344892B2 (en) 2018-08-28 2025-07-01 10X Genomics, Inc. Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample
WO2020047010A2 (fr) 2018-08-28 2020-03-05 10X Genomics, Inc. Augmentation de la résolution d'un réseau spatial
WO2020047004A2 (fr) 2018-08-28 2020-03-05 10X Genomics, Inc. Procédés permettant de générer un réseau
US12270077B2 (en) 2018-08-28 2025-04-08 10X Genomics, Inc. Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample
NL2022043B1 (en) 2018-11-21 2020-06-03 Akershus Univ Hf Tagmentation-Associated Multiplex PCR Enrichment Sequencing
WO2020104851A1 (fr) 2018-11-21 2020-05-28 Akershus Universitetssykehus Hf Séquençage d'enrichissement de pcr multiplex associé à une tagmentation
WO2020114918A1 (fr) 2018-12-05 2020-06-11 Illumina Cambridge Limited Procédés et compositions pour la génération de grappes par amplification en pont
WO2020123301A2 (fr) 2018-12-10 2020-06-18 10X Genomics, Inc. Génération de réseaux spatiaux avec des gradients
WO2020123316A2 (fr) 2018-12-10 2020-06-18 10X Genomics, Inc. Procédés de détermination d'un emplacement d'un analyte biologique dans un échantillon biologique
WO2020123309A1 (fr) 2018-12-10 2020-06-18 10X Genomics, Inc. Résolution de réseaux spatiaux par déconvolution basée sur la proximité
WO2020123305A2 (fr) 2018-12-10 2020-06-18 10X Genomics, Inc. Génération de sondes de capture pour analyse spatiale
US12404544B2 (en) 2018-12-10 2025-09-02 10X Genomics, Inc. Methods of capturing multiple analytes on a spatial array
WO2020123318A1 (fr) 2018-12-10 2020-06-18 10X Genomics, Inc. Résolution de réseaux spatiaux à l'aide d'une déconvolution
US12024741B2 (en) 2018-12-10 2024-07-02 10X Genomics, Inc. Imaging system hardware
WO2020123317A2 (fr) 2018-12-10 2020-06-18 10X Genomics, Inc Analyse spatiale tridimensionnelle
WO2020123311A2 (fr) 2018-12-10 2020-06-18 10X Genomics, Inc. Résolution de réseaux spatiaux à l'aide d'une déconvolution
US12180543B2 (en) 2018-12-10 2024-12-31 10X Genomics, Inc. Imaging system hardware
US12385083B2 (en) 2018-12-10 2025-08-12 10X Genomics, Inc. Methods of using master / copy arrays for spatial detection
EP4567127A2 (fr) 2018-12-10 2025-06-11 10x Genomics, Inc. Procédés de détermination d'un emplacement d'un analyte biologique dans un échantillon biologique
US11933957B1 (en) 2018-12-10 2024-03-19 10X Genomics, Inc. Imaging system hardware
WO2020123319A2 (fr) 2018-12-10 2020-06-18 10X Genomics, Inc. Procédés d'utilisation de réseaux maître/copie pour la détection spatiale
WO2020120179A1 (fr) 2018-12-14 2020-06-18 Illumina Cambridge Limited Réduction du phasage avec des nucléotides non marqués pendant le séquençage
CN112639126A (zh) * 2018-12-14 2021-04-09 伊卢米纳剑桥有限公司 降低测序期间用未标记的核苷酸的定相
US11767558B2 (en) 2018-12-14 2023-09-26 Illumina Cambridge Limited Adding nucleotides during sequence detection
US20200190576A1 (en) * 2018-12-14 2020-06-18 Illumina Cambridge Limited Adding nucleotides during sequence detection
WO2020126593A1 (fr) 2018-12-17 2020-06-25 Illumina Cambridge Limited Compositions destinées à être utilisées dans le séquençage de polynucléotides
WO2020126595A1 (fr) 2018-12-17 2020-06-25 Illumina Cambridge Limited Oligonucléotide d'amorce pour le séquençage
WO2020126602A1 (fr) 2018-12-18 2020-06-25 Illumina Cambridge Limited Procédés et compositions pour séquençage d'extrémités appariées à l'aide d'une amorce de surface unique
WO2020132103A1 (fr) 2018-12-19 2020-06-25 Illumina, Inc. Procédés d'amélioration de la priorité de la clonalité d'un ensemble de polynucléotides
US11649485B2 (en) 2019-01-06 2023-05-16 10X Genomics, Inc. Generating capture probes for spatial analysis
US11926867B2 (en) 2019-01-06 2024-03-12 10X Genomics, Inc. Generating capture probes for spatial analysis
US11753675B2 (en) 2019-01-06 2023-09-12 10X Genomics, Inc. Generating capture probes for spatial analysis
WO2020176788A1 (fr) 2019-02-28 2020-09-03 10X Genomics, Inc. Profilage d'analytes biologiques avec des réseaux d'oligonucléotides à codes-barres spatiaux
WO2020180778A1 (fr) 2019-03-01 2020-09-10 Illumina, Inc. Banques de noyaux uniques et à cellule unique à haut rendement et leurs procédés de production et d'utilisation
WO2020190509A1 (fr) 2019-03-15 2020-09-24 10X Genomics, Inc. Méthodes d'utilisation de matrices spatiales pour le séquençage d'organismes unicellulaires
US12277998B2 (en) 2019-03-21 2025-04-15 Illumina, Inc. Artificial intelligence-based base calling
US11783917B2 (en) 2019-03-21 2023-10-10 Illumina, Inc. Artificial intelligence-based base calling
NL2023316B1 (en) 2019-03-21 2020-09-28 Illumina Inc Artificial intelligence-based sequencing
NL2023312B1 (en) 2019-03-21 2020-09-28 Illumina Inc Artificial intelligence-based base calling
US12119088B2 (en) 2019-03-21 2024-10-15 Illumina, Inc. Deep neural network-based sequencing
WO2020205296A1 (fr) 2019-03-21 2020-10-08 Illumina, Inc. Génération à base d'intelligence artificielle de métadonnées de séquençage
NL2023314B1 (en) 2019-03-21 2020-09-28 Illumina Inc Artificial intelligence-based quality scoring
WO2020191391A2 (fr) 2019-03-21 2020-09-24 Illumina, Inc. Séquençage à base d'intelligence artificielle
US12217831B2 (en) 2019-03-21 2025-02-04 Illumina, Inc. Artificial intelligence-based quality scoring
US11676685B2 (en) 2019-03-21 2023-06-13 Illumina, Inc. Artificial intelligence-based quality scoring
US11908548B2 (en) 2019-03-21 2024-02-20 Illumina, Inc. Training data generation for artificial intelligence-based sequencing
EP4276769A2 (fr) 2019-03-21 2023-11-15 Illumina, Inc. Génération de données d'apprentissage pour séquençage à base d'intelligence artificielle
NL2023310B1 (en) 2019-03-21 2020-09-28 Illumina Inc Training data generation for artificial intelligence-based sequencing
NL2023311B1 (en) 2019-03-21 2020-09-28 Illumina Inc Artificial intelligence-based generation of sequencing metadata
US11961593B2 (en) 2019-03-21 2024-04-16 Illumina, Inc. Artificial intelligence-based determination of analyte data for base calling
WO2020191389A1 (fr) 2019-03-21 2020-09-24 Illumina, Inc. Génération de données d'apprentissage pour séquençage à base d'intelligence artificielle
WO2020198071A1 (fr) 2019-03-22 2020-10-01 10X Genomics, Inc. Analyse spatiale tridimensionnelle
US11593649B2 (en) 2019-05-16 2023-02-28 Illumina, Inc. Base calling using convolutions
US12237052B2 (en) 2019-05-16 2025-02-25 Illumina, Inc. Base calling using convolution
US11817182B2 (en) 2019-05-16 2023-11-14 Illumina, Inc. Base calling using three-dimentional (3D) convolution
US12106828B2 (en) 2019-05-16 2024-10-01 Illumina, Inc. Systems and devices for signal corrections in pixel-based sequencing
US12442045B2 (en) 2019-05-30 2025-10-14 10X Genomics, Inc. Methods of detecting spatial heterogeneity of a biological sample
US11965213B2 (en) 2019-05-30 2024-04-23 10X Genomics, Inc. Methods of detecting spatial heterogeneity of a biological sample
WO2020243579A1 (fr) 2019-05-30 2020-12-03 10X Genomics, Inc. Procédés de détection de l'hétérogénéité spatiale d'un échantillon biologique
WO2021008805A1 (fr) 2019-07-12 2021-01-21 Illumina Cambridge Limited Compositions et procédés de préparation de bibliothèques de séquençage d'acide nucléique à l'aide de crispr/cas9 immobilisé sur un support solide
EP3798319A1 (fr) 2019-09-30 2021-03-31 Diagenode S.A. Procédé de diagnostic et/ou de séquençage amélioré et kit
US11788137B2 (en) 2019-09-30 2023-10-17 Diagenode S.A. Diagnostic and/or sequencing method and kit
US11514575B2 (en) 2019-10-01 2022-11-29 10X Genomics, Inc. Systems and methods for identifying morphological patterns in tissue samples
US12125260B2 (en) 2019-10-01 2024-10-22 10X Genomics, Inc. Systems and methods for identifying morphological patterns in tissue samples
US11592447B2 (en) 2019-11-08 2023-02-28 10X Genomics, Inc. Spatially-tagged analyte capture agents for analyte multiplexing
US11808769B2 (en) 2019-11-08 2023-11-07 10X Genomics, Inc. Spatially-tagged analyte capture agents for analyte multiplexing
WO2021091611A1 (fr) 2019-11-08 2021-05-14 10X Genomics, Inc. Agents de capture d'analytes marqués spatialement pour le multiplexage d'analytes
US12154266B2 (en) 2019-11-18 2024-11-26 10X Genomics, Inc. Systems and methods for binary tissue classification
WO2021102039A1 (fr) 2019-11-21 2021-05-27 10X Genomics, Inc, Analyse spatiale d'analytes
EP4538971A2 (fr) 2019-11-21 2025-04-16 10x Genomics, Inc. Analyse spatiale d'analytes
EP3828283A1 (fr) 2019-11-28 2021-06-02 Diagenode S.A. Procédé et kit de séquençage améliorés
WO2021123074A1 (fr) 2019-12-18 2021-06-24 F. Hoffmann-La Roche Ag Procédés de séquençage par synthèse au moyen d'un schéma de marquage consécutif
WO2021127436A2 (fr) 2019-12-19 2021-06-24 Illumina, Inc. Banques de cellules uniques à haut débit et leurs procédés de production et d'utilisation
US12110541B2 (en) 2020-02-03 2024-10-08 10X Genomics, Inc. Methods for preparing high-resolution spatial arrays
US12112833B2 (en) 2020-02-04 2024-10-08 10X Genomics, Inc. Systems and methods for index hopping filtering
US12421558B2 (en) 2020-02-13 2025-09-23 10X Genomics, Inc. Systems and methods for joint interactive visualization of gene expression and DNA chromatin accessibility
US12215379B2 (en) 2020-02-17 2025-02-04 10X Genomics, Inc. In situ analysis of chromatin interaction
US12443849B2 (en) 2020-02-20 2025-10-14 Illumina, Inc. Bus network for artificial intelligence-based base caller
WO2021168018A1 (fr) 2020-02-20 2021-08-26 Illumina, Inc. Exécution et accélération matérielle d'un appelant de base à base d'intelligence artificielle
US12106829B2 (en) 2020-02-20 2024-10-01 Illumina, Inc. Artificial intelligence-based many-to-many base calling
US12354008B2 (en) 2020-02-20 2025-07-08 Illumina, Inc. Knowledge distillation and gradient pruning-based compression of artificial intelligence-based base caller
US11749380B2 (en) 2020-02-20 2023-09-05 Illumina, Inc. Artificial intelligence-based many-to-many base calling
US12173360B2 (en) 2020-02-21 2024-12-24 10X Genomics, Inc. Methods and compositions for integrated in situ spatial assay
EP4484571A2 (fr) 2020-02-21 2025-01-01 10X Genomics, Inc. Procédés et compositions pour un dosage spatial in situ intégré
WO2021168287A1 (fr) 2020-02-21 2021-08-26 10X Genomics, Inc. Méthodes et compositions pour dosage spatial in situ intégré
US12188085B2 (en) 2020-03-05 2025-01-07 10X Genomics, Inc. Three-dimensional spatial transcriptomics with sequencing readout
WO2021226523A2 (fr) 2020-05-08 2021-11-11 Illumina, Inc. Techniques de séquençage et de détection de génome
WO2021226522A1 (fr) 2020-05-08 2021-11-11 Illumina, Inc. Techniques de séquençage et de détection de génome
WO2021231477A2 (fr) 2020-05-12 2021-11-18 Illumina, Inc. Génération d'acides nucléiques avec des bases modifiées au moyen de désoxynucléotidyl transférase terminale recombinante
WO2021252375A1 (fr) 2020-06-08 2021-12-16 The Broad Institute, Inc. Indexation combinatoire à cellule unique, à partir d'acides nucléiques amplifiés
WO2021252617A1 (fr) 2020-06-09 2021-12-16 Illumina, Inc. Procédés pour augmenter le rendement de bibliothèques de séquençage
WO2022006081A1 (fr) 2020-06-30 2022-01-06 Illumina, Inc. Séquençage à commande catalytique par synthèse pour produire de l'adn sans scarification
US12168801B1 (en) 2020-07-02 2024-12-17 10X Genomics, Inc. Hybrid/capture probe designs for full-length cDNA
WO2022010965A1 (fr) 2020-07-08 2022-01-13 Illumina, Inc. Billes utilisées en tant que supports pour transposomes
US12071667B2 (en) 2020-11-04 2024-08-27 10X Genomics, Inc. Sequence analysis using meta-stable nucleic acid molecules
WO2022119812A1 (fr) 2020-12-02 2022-06-09 Illumina Software, Inc. Système et procédé pour la détection d'altérations génétiques
WO2022164809A1 (fr) 2021-01-26 2022-08-04 10X Genomics, Inc. Sondes analogiques d'acide nucléique pour analyse in situ
EP4488385A2 (fr) 2021-01-26 2025-01-08 10x Genomics, Inc. Sondes analogiques d'acide nucléique pour analyse in situ
WO2022197752A1 (fr) 2021-03-16 2022-09-22 Illumina, Inc. Sélection d'ensembles de poids basée sur l'emplacement d'un élément et/ou le cycle pour appel de base
WO2022204032A1 (fr) 2021-03-22 2022-09-29 Illumina Cambridge Limited Procédés d'amélioration de la clonalité de groupes d'acides nucléiques
WO2022207804A1 (fr) 2021-03-31 2022-10-06 Illumina Cambridge Limited Techniques de séquençage de bibliothèque d'acides nucléiques avec détection de dimères adaptateurs
WO2022213027A1 (fr) 2021-04-02 2022-10-06 Illumina, Inc. Modèle d'apprentissage automatique pour la détection d'une bulle dans une lame d'échantillon de nucléotide pour séquençage
US12444482B2 (en) 2021-04-15 2025-10-14 Illumina, Inc. Multi-channel protein voxelization to predict variant pathogenicity using deep convolutional neural networks
US11515010B2 (en) 2021-04-15 2022-11-29 Illumina, Inc. Deep convolutional neural networks to predict variant pathogenicity using three-dimensional (3D) protein structures
US12217829B2 (en) 2021-04-15 2025-02-04 Illumina, Inc. Artificial intelligence-based analysis of protein three-dimensional (3D) structures
FR3121935A1 (fr) 2021-04-20 2022-10-21 Naos Institute Of Life Science Methode de selection d’ingredients et de compositions topiques ecobiologiques aptes a restaurer ou renforcer le microbiote cutane
WO2022223928A1 (fr) 2021-04-20 2022-10-27 Naos Institute Of Life Science Methode de selection d'ingredients et de compositions topiques ecobiologiques aptes a restaurer ou renforcer le microbiote cutane
FR3121936A1 (fr) 2021-04-20 2022-10-21 Naos Institute Of Life Science Methode de criblage d’ingredients et de compositions topiques ecobiologiques, et son utilisation pour realiser un soin cosmetique de restauration du microbiote cutane
WO2022232425A2 (fr) 2021-04-29 2022-11-03 Illumina, Inc. Techniques d'amplification pour la caractérisation d'acides nucléiques
WO2022251510A2 (fr) 2021-05-28 2022-12-01 Illumina, Inc. Analogues de nucléotides oligo-modifiés pour la préparation d'acides nucléiques
WO2022256229A1 (fr) 2021-06-03 2022-12-08 Illumina Cambridge Limited Systèmes et procédés de séquençage de nucléotides à l'aide de deux canaux optiques
WO2022272260A1 (fr) 2021-06-23 2022-12-29 Illumina, Inc. Compositions, procédés, kits, cartouches et systèmes de séquençage de réactifs
WO2022271954A1 (fr) 2021-06-24 2022-12-29 Illumina, Inc. Procédés et compositions pour l'indexation combinatoire d'acides nucléiques à base de billes
WO2023278609A1 (fr) 2021-06-29 2023-01-05 Illumina, Inc. Appelant de base auto-appris, entraîné à l'aide de séquences d'organismes
WO2023278184A1 (fr) 2021-06-29 2023-01-05 Illumina, Inc. Procédés et systèmes pour corriger une diaphonie dans un éclairage émis par des sites de réaction
US12217403B2 (en) 2021-06-29 2025-02-04 Illumina, Inc. Methods and systems to correct crosstalk in illumination emitted from reaction sites
WO2023278608A1 (fr) 2021-06-29 2023-01-05 Illumina, Inc. Organe d'appel de base auto-appris, entraîné à l'aide d'oligo-séquences
WO2023278927A1 (fr) 2021-06-29 2023-01-05 Illumina Software, Inc. Métrique de rapport signal-sur-bruit pour déterminer des identifications de bases nucléotidiques et qualité d'identification de bases
WO2023278966A1 (fr) 2021-06-29 2023-01-05 Illumina, Inc. Modèle d'apprentissage automatique pour générer des classifications de confiance pour des coordonnées génomiques
WO2023278788A1 (fr) 2021-07-01 2023-01-05 Illumina, Inc. Appel de base reposant sur l'intelligence artificielle efficace de séquences d'index
WO2023287617A1 (fr) 2021-07-13 2023-01-19 Illumina, Inc. Procédés et systèmes pour l'extraction en temps réel de diaphonie dans un éclairage émis à partir de sites de réaction
US12423815B2 (en) 2021-07-13 2025-09-23 Illumina, Inc. Methods and systems for real time extraction of crosstalk in illumination emitted from reaction sites
WO2023003757A1 (fr) 2021-07-19 2023-01-26 Illumina Software, Inc. Extraction d'intensité avec interpolation et adaptation pour appel de base
WO2023004323A1 (fr) 2021-07-23 2023-01-26 Illumina Software, Inc. Modèle d'apprentissage automatique pour réétalonner des appels de base de nucléotides
WO2023009758A1 (fr) 2021-07-28 2023-02-02 Illumina, Inc. Étalonnage de score de qualité de systèmes d'appel de bases
WO2023014741A1 (fr) 2021-08-03 2023-02-09 Illumina Software, Inc. Assignation de bases utilisant de multiples modèles de systèmes d'assignation de bases
WO2023034079A1 (fr) 2021-09-01 2023-03-09 Illumina Software, Inc. Modulation d'amplitude pour identification de base accélérée
WO2023035108A1 (fr) * 2021-09-07 2023-03-16 深圳华大智造科技股份有限公司 Procédé d'analyse de la séquence d'un polynucléotide cible
WO2023035110A1 (fr) * 2021-09-07 2023-03-16 深圳华大智造科技股份有限公司 Procédé d'analyse de séquence de polynucléotide cible
CN115917006A (zh) * 2021-09-07 2023-04-04 深圳华大智造科技股份有限公司 一种用于分析靶多核苷酸的序列的方法
WO2023044229A1 (fr) 2021-09-17 2023-03-23 Illumina, Inc. Identification automatique de sources de défaillance en séquençage nucléotidique à partir de motifs d'erreur d'appel de base
WO2023049558A1 (fr) 2021-09-21 2023-03-30 Illumina, Inc. Génome de référence de graphe et stratégie d'appel de bases utilisant des haplotypes attribués
WO2023052427A1 (fr) 2021-09-30 2023-04-06 Illumina Cambridge Limited Séquençage de polynucléotides
US12195790B2 (en) 2021-12-01 2025-01-14 10X Genomics, Inc. Methods for improved in situ detection of nucleic acids and spatial analysis
WO2023102118A2 (fr) 2021-12-01 2023-06-08 10X Genomics, Inc. Procédés, compositions et systèmes pour la détection améliorée d'analytes in situ et analyse spatiale
WO2023102354A1 (fr) 2021-12-02 2023-06-08 Illumina Software, Inc. Génération de corrections de signal spécifique à un groupe pour déterminer des appels de base nucléotidique
WO2023107622A1 (fr) 2021-12-10 2023-06-15 Illumina, Inc. Séquençage d'échantillons et d'indices parallèles
WO2023122363A1 (fr) 2021-12-23 2023-06-29 Illumina Software, Inc. Résumés dynamiques d'état graphique pour séquençage de nucléotides
WO2023122362A1 (fr) 2021-12-23 2023-06-29 Illumina Software, Inc. Facilitation de l'exécution sécurisée de flux de travail externes pour des diagnostics de séquençage génomique
WO2023129896A1 (fr) 2021-12-28 2023-07-06 Illumina Software, Inc. Modèle d'apprentissage automatique pour réétalonner des appels de base nucléotidiques correspondant à des variants cibles
WO2023129764A1 (fr) 2021-12-29 2023-07-06 Illumina Software, Inc. Permutation automatique des versions de modèle d'analyse de variants pour les applications d'analyse génomique
WO2023126457A1 (fr) 2021-12-29 2023-07-06 Illumina Cambridge Ltd. Procédés de séquençage d'acide nucléique à l'aide d'amorces liées à une surface
WO2023164492A1 (fr) 2022-02-25 2023-08-31 Illumina, Inc. Modèles d'apprentissage automatique destinés à détecter et ajuster des valeurs pour des niveaux de méthylation de nucléotides
WO2023164660A1 (fr) 2022-02-25 2023-08-31 Illumina, Inc. Séquences d'étalonnage à des fins de séquençage de nucléotide
WO2023175026A1 (fr) 2022-03-15 2023-09-21 Illumina, Inc. Procédés de détermination d'informations de séquence
WO2023175043A1 (fr) 2022-03-15 2023-09-21 Illumina, Inc. Procédés de reconnaissance de bases pour nucléobases
WO2023175042A1 (fr) 2022-03-15 2023-09-21 Illumina, Inc. Séquençage d'échantillons et d'indices parallèles
WO2023175024A1 (fr) 2022-03-15 2023-09-21 Illumina, Inc. Séquençage d'extrémité appariée
US12234507B2 (en) 2022-04-01 2025-02-25 10X Genomics, Inc. Compositions and methods for targeted masking of autofluorescence
WO2023192616A1 (fr) 2022-04-01 2023-10-05 10X Genomics, Inc. Compositions et procédés de masquage ciblé d'autofluorescence
WO2023196526A1 (fr) 2022-04-06 2023-10-12 10X Genomics, Inc. Procédés d'analyse multiplex de cellules
WO2023196572A1 (fr) 2022-04-07 2023-10-12 Illumina Singapore Pte. Ltd. Cytidine désaminases modifiées et méthodes d'utilisation
WO2023196528A1 (fr) 2022-04-08 2023-10-12 Illumina, Inc. Techniques de détection et de compression de plage dynamique d'aptamères
WO2023212601A1 (fr) 2022-04-26 2023-11-02 Illumina, Inc. Modèles d'apprentissage automatique pour sélectionner des sondes oligonucléotidiques pour des technologies de réseau
WO2023209606A1 (fr) 2022-04-29 2023-11-02 Illumina Cambridge Limited Procédés et systèmes d'encapsulation de microsphères lyophilisées
WO2023215612A1 (fr) 2022-05-06 2023-11-09 10X Genomics, Inc. Analyse d'un antigène et des interactions antigène-récepteur
WO2023220627A1 (fr) 2022-05-10 2023-11-16 Illumina Software, Inc. Réseau neuronal adaptatif pour séquençage de nucléotides
WO2023225095A1 (fr) 2022-05-18 2023-11-23 Illumina Cambridge Limited Préparation de fragments d'acide nucléique à taille contrôlée
WO2023250504A1 (fr) 2022-06-24 2023-12-28 Illumina Software, Inc. Amélioration d'alignement de lecture de division en identifiant et en évaluant de manière intelligente des groupes de divisions candidats
WO2024006779A1 (fr) 2022-06-27 2024-01-04 Illumina, Inc. Accélérateurs pour un modèle d'imputation de génotypes
WO2024006769A1 (fr) 2022-06-27 2024-01-04 Illumina Software, Inc. Génération et mise en œuvre d'un génome à graphe de variation structurelle
WO2024006705A1 (fr) 2022-06-27 2024-01-04 Illumina Software, Inc. Génotypage amélioré d'antigène leucocytaire humain (hla)
WO2024026356A1 (fr) 2022-07-26 2024-02-01 Illumina, Inc. Traitement multiomique à cellule unique rapide à l'aide d'un fichier exécutable
WO2024050820A1 (fr) * 2022-09-09 2024-03-14 深圳华大智造科技股份有限公司 Composition antioxydante et son utilisation dans la détection d'acides nucléiques
WO2024059852A1 (fr) 2022-09-16 2024-03-21 Illumina, Inc. Segmentation de grappes et appel de bases conditionnel
WO2024073516A1 (fr) 2022-09-29 2024-04-04 Illumina, Inc. Panneau de référence de variant cible servant à imputer des variants cibles
WO2024069581A1 (fr) 2022-09-30 2024-04-04 Illumina Singapore Pte. Ltd. Complexes hélicase-cytidine désaminase et procédés d'utilisation
WO2024073043A1 (fr) 2022-09-30 2024-04-04 Illumina, Inc. Procédés d'utilisation de protéines de liaison cpg dans la cartographie de nucléotides cytosine modifiés
WO2024073047A1 (fr) 2022-09-30 2024-04-04 Illumina, Inc. Cytidine désaminases et procédés d'utilisation dans la cartographie de nucléotides cytosine modifiés
WO2024073519A1 (fr) 2022-09-30 2024-04-04 Illumina, Inc. Modèle d'apprentissage automatique pour affiner des appels de variants structuraux
WO2024077096A1 (fr) 2022-10-05 2024-04-11 Illumina, Inc. Intégration d'appels de variants à partir de multiples pipelines de séquençage à l'aide d'une architecture d'apprentissage automatique
WO2024081649A1 (fr) 2022-10-11 2024-04-18 Illumina, Inc. Détection et correction de valeurs de méthylation à partir de dosages de séquençage de méthylation
WO2024118791A1 (fr) 2022-11-30 2024-06-06 Illumina, Inc. Prédiction précise de variants à partir de données de séquençage de méthylation
WO2024118903A1 (fr) 2022-11-30 2024-06-06 Illumina, Inc. Correction chimio-enzymatique de transformations d'uracile faux positives
WO2024137886A1 (fr) 2022-12-21 2024-06-27 Illumina, Inc. Appel de base dépendant du contexte
WO2024147904A1 (fr) 2023-01-06 2024-07-11 Illumina, Inc. Réduction des uraciles par polymérase
WO2024167954A1 (fr) 2023-02-06 2024-08-15 Illumina, Inc. Détermination et élimination d'interférence de lumière inter-groupes
WO2024191806A1 (fr) 2023-03-10 2024-09-19 Illumina, Inc. Techniques de détection d'aptamères
WO2024206848A1 (fr) 2023-03-30 2024-10-03 Illumina, Inc. Génotypage à répétition en tandem
WO2024229396A1 (fr) 2023-05-03 2024-11-07 Illumina, Inc. Modèle d'apprentissage automatique pour réétalonner des appels de génotype à partir de fichiers de données de séquençage existants
WO2024249200A1 (fr) 2023-05-26 2024-12-05 Illumina, Inc. Procédés de conservation de l'état de méthylation pendant le regroupement
WO2024249466A1 (fr) 2023-05-31 2024-12-05 Illumina, Inc. Réduction de faux positifs par réparation de polymérase par translésion
WO2024249591A1 (fr) 2023-05-31 2024-12-05 Illumina, Inc. Procédés de séquençage double brin par synthèse
WO2024249940A1 (fr) 2023-05-31 2024-12-05 Illumina, Inc. Amélioration d'un alignement de variants structuraux et appel de variant à l'aide d'un génome de référence de variant structural
WO2024249973A2 (fr) 2023-06-02 2024-12-05 Illumina, Inc. Liaison de gènes humains à des phénotypes cliniques à l'aide de réseaux neuronaux graphiques
WO2025006565A1 (fr) 2023-06-27 2025-01-02 Illumina, Inc. Appel de variant avec estimation du niveau de méthylation
WO2025006460A1 (fr) 2023-06-30 2025-01-02 Illumina, Inc. Systèmes et procédés de séquençage de polynucléotides à bases modifiées
WO2025006874A1 (fr) 2023-06-30 2025-01-02 Illumina, Inc. Modèle d'apprentissage automatique pour réétalonner des appels de génotype correspondant à des variants de lignée germinale et variants de mosaïque somatique
WO2025006464A1 (fr) 2023-06-30 2025-01-02 Illumina, Inc. Systèmes et procédés de séquençage de polynucléotides avec des diagrammes de dispersion alternatifs
WO2025006466A1 (fr) 2023-06-30 2025-01-02 Illumina, Inc. Systèmes et procédés de séquençage de polynucléotides avec quatre nucléotides marqués
WO2025049720A2 (fr) 2023-08-31 2025-03-06 Illumina, Inc. Techniques de détection et de compression de plage dynamique d'aptamères
WO2025049331A2 (fr) 2023-08-31 2025-03-06 Illumina, Inc. Techniques de détection d'aptamères
WO2025054389A1 (fr) 2023-09-07 2025-03-13 Illumina, Inc. Identification de la cytosine méthylée par l'utilisation de points de repère
EP4520821A1 (fr) 2023-09-08 2025-03-12 The Regents Of The University Of Michigan Arn et polypeptides dérivés de microarn et leurs utilisations
WO2025061922A1 (fr) 2023-09-20 2025-03-27 Illumina, Inc. Procédés de séquençage
WO2025061942A1 (fr) 2023-09-20 2025-03-27 Illumina, Inc. Identification et correction d'erreur de séquençage
WO2025072800A2 (fr) 2023-09-28 2025-04-03 Illumina, Inc. Cytidine désaminases modifiées et procédés d'utilisation
WO2025072793A1 (fr) 2023-09-28 2025-04-03 Illumina, Inc. Cytidine désaminases modifiées et procédés d'utilisation
WO2025072783A1 (fr) 2023-09-28 2025-04-03 Illumina, Inc. Cytidine désaminases modifiées et méthodes d'utilisation
WO2025072870A1 (fr) 2023-09-29 2025-04-03 Illumina, Inc. Suivi et modification d'emplacement de cluster sur des lames d'échantillon de nucléotides en temps réel
WO2025072833A1 (fr) 2023-09-29 2025-04-03 Illumina, Inc. Prédiction de longueurs d'insert à l'aide de métriques d'analyse primaire
WO2025081064A2 (fr) 2023-10-11 2025-04-17 Illumina, Inc. Désaminase thermophile et procédés d'identification de cytosine modifiée
WO2025090883A1 (fr) 2023-10-27 2025-05-01 Illumina, Inc. Détection de variants dans des séquences nucléotidiques sur la base d'une diversité d'haplotype
WO2025117738A1 (fr) 2023-11-28 2025-06-05 Illumina, Inc. Procédés d'amélioration d'efficacité de ligature d'indice moléculaire unique
WO2025123005A2 (fr) 2023-12-07 2025-06-12 Illumina, Inc. Préparation et compositions d'acide nucléique cot-1
WO2025129133A1 (fr) 2023-12-15 2025-06-19 Illumina, Inc. Modèles de maladie résiduelle minime (mrd) pour déterminer des probabilités qu'un sujet comprenne un cancer
WO2025136998A1 (fr) 2023-12-18 2025-06-26 Illumina, Inc. Utilisation de modèles d'apprentissage automatique pour détecter une maladie résiduelle minimale (mrd) chez un sujet
WO2025137222A1 (fr) 2023-12-19 2025-06-26 Illumina, Inc. Dosage de détection de méthylation
WO2025137341A1 (fr) 2023-12-20 2025-06-26 Illumina, Inc. Détermination directe de mesures de rapport signal sur bruit pour une convergence accélérée lors de la détermination d'appels de base nucléotidique et d'une qualité d'appel de base
WO2025137647A1 (fr) 2023-12-21 2025-06-26 Illumina, Inc. Mappage et alignement améliorés de lectures de nucléotides à l'aide d'une structure de données d'haplotype améliorée avec des différences allèle-variant
WO2025144626A1 (fr) 2023-12-28 2025-07-03 Illumina, Inc. Séquençage avec protéines de liaison simple brin
WO2025160089A1 (fr) 2024-01-26 2025-07-31 Illumina, Inc. Construction de référence multigénome personnalisée pour une analyse de séquençage améliorée d'échantillons génomiques
WO2025174774A1 (fr) 2024-02-12 2025-08-21 Illumina, Inc. Détermination de corrections hors ligne pour des erreurs spécifiques de séquence provoquées par des séquences nucléotidiques de faible complexité
WO2025174708A1 (fr) 2024-02-13 2025-08-21 Illumina, Inc. Conception et procédé de compatibilité inter-plateformes de séquençage de cuves à circulation
WO2025178951A1 (fr) 2024-02-22 2025-08-28 Illumina, Inc. Techniques de regroupement par compression de la plage dynamique dans les dosages d'analytes
WO2025184234A1 (fr) 2024-02-28 2025-09-04 Illumina, Inc. Base de données d'haplotypes personnalisée pour mappage et alignement améliorés de lectures de nucléotides et appel de génotype amélioré
WO2025193747A1 (fr) 2024-03-12 2025-09-18 Illumina, Inc. Modèles d'apprentissage automatique pour ordonner et accélérer les tâches de séquençage ou les lames d'échantillons de nucléotides correspondantes
WO2025207535A1 (fr) 2024-03-26 2025-10-02 Illumina, Inc. Surfaces photocommutables
WO2025217057A1 (fr) 2024-04-08 2025-10-16 Illumina, Inc. Détection de variante à l'aide d'alignements de données de séquence améliorés
WO2025240241A1 (fr) 2024-05-13 2025-11-20 Illumina, Inc. Modification de cycles de séquençage pendant une analyse de séquençage pour satisfaire des estimations de couverture personnalisées pour une région génomique cible
WO2025240924A1 (fr) 2024-05-17 2025-11-20 Illumina, Inc. Systèmes d'égalisation aveugle pour applications d'appel de base

Also Published As

Publication number Publication date
EP1828412B2 (fr) 2019-01-09
EP1828412A1 (fr) 2007-09-05
EP1828412B1 (fr) 2012-11-28

Similar Documents

Publication Publication Date Title
EP1828412B1 (fr) Procede ameliore de detection de nucleotides
US9970055B2 (en) Method of nucleotide detection
US20230193384A1 (en) Method for sequencing a polynucleotide template
US10876158B2 (en) Method for sequencing a polynucleotide template
JP2023531463A (ja) 酵素的核酸伸長を用いたｉｎ ｓｉｔｕ単一細胞解析のための組成物及び方法
EP1910559A2 (fr) Preparation de matrices pour sequencage d'acides nucleiques
JP2009254279A (ja) 核酸類の配列選択的な精製方法
US20090117621A1 (en) Methods of nucleic acid amplification and sequencing
CA3223274A1 (fr) Compositions de periodate et methodes de clivage chimique de polynucleotides lies a la surface
CA3222829A1 (fr) Procedes de clivage dirige par metal de polynucleotides lies a une surface

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005818529

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005818529

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11792878

Country of ref document: US